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Abstract
In Molecular Radiation Therapy, the estimation of energy absorbed within tissue is
critical for the assessment of the efficacy of radiopharmaceuticals. Computational
phantoms are a valuable tool to estimate radiation dose and to ensure that radiation dose to healthy tissue is minimised whilst still achieving a therapeutic level of
radiation dose to disease cells.
The International Commission on Radiological Protection (ICRP) has published several computational phantoms for the radiation protection of the population, amongst
these are female and male adult voxelised phantoms (ICRP Publication 110) and
adult mesh reference phantoms (ICRP Publication 145). The ICRP 110 voxelised
phantoms have been widely used for the investigation of radiation dose from internalization of radionuclides. The ICRP 145 mesh phantom has multiple advantages
compared to the voxel phantom, with the ability to morph the phantom, as well as
create more accurate organ shapes with the availability of rendering software. The
aim of this study was to implement the latter in the Geant4/GATE Monte Carlo
tool and assess its performance when compared to the ICRP 110 phantom, of which
it is an adaptation.
The ICRP 145 mesh phantom was implemented in the Geant4/GATE Monte Carlo
simulation environment, making use of the Geant4 C++ classes allowing recording
dose in a mesh geometry. Radiation doses to lungs, kidneys, pancreas and spleen of
the ICRP 145 adult phantoms were estimated from the distributions of Holmium166, Lutetium-177 and Yttrium-90 in spherical hepatic lesions of sizes ranging between 0.1 and 3 cm. These were then compared with radiation doses estimated
using the voxelised ICRP 110 phantoms for the same lesions. These absorbed dose
values were used to calculate S -values, the mean absorbed dose to a target organ
per unit cumulated activity in a source organ. This S -value is a specific value for
radionuclides and phantoms which describe dose to a target organ. These radionuclides were chosen as candidates in hepatic radioembolization using microspheres
and to investigate their impact on radiation dose to healthy surrounding organs.
Significant differences in the radiation deposited in organs can were noted between
the ICRP 145 and the ICRP 110 phantoms. This is due to the differences in mass
and volume of organs and tissues between the two phantoms, this also is the reason for variation between male and female phantoms. However when the mass
dependence was removed, the dose deposited to the liver was similar to that of
the ICRP 110 phantoms. However, in this study and for the organs investigated
outside the liver (kidneys, pancreas and lungs) the coefficient of variation was as
large as 100% due to low hits. As expected, the radionuclide giving the maximum
dose to the surrounding tissues is Y-90 (with an S -value Right Lung ← Lesion of
1.296 × 10−9 mGyM Bq −1 s−1 compared to 5.023 × 10−11 mGyM Bq −1 s−1 for Ho-166
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and 4.190 × 10−11 mGyM Bq −1 s−1 for Lu-177) while the radionuclide depositing the
maximal energy locally was Lu-177.

Acknowledgments
I would like to thank Dr. Alessandra Malaroda for allowing me to conduct this
research project through the University of Wollongong. Her knowledge and expertise in the field is second to none, and I have benefited greatly from working with her.
I would like to thank my co-supervisor Dr. Susanna Guatelli. Dr Guatelli ensured
this project ran smoothly and the final thesis is of the top quality. Dr Guatelli’s
expertise in Geant4 has allowed us to ensure the simulations conducted have statistical significance, and are physically precise.
I would like to also thank Professor Alexey Pan for his assistance in thesis writing, literature and presentation skills. Alexey’s insight and encouragement to create
presentations of the highest standard have allowed me to excel in presenting.
I would like to thank David Bolst. David was instrumental in helping me to access and operate the NCI cluster, and ensure our simulations ran smoothly.
I would like to thank Distinguished Professor Anatoly Rosenfeld, for inspiring me to
follow the path I currently find myself on, and pursuing a career in Nuclear Medicine.
I am also incredibly blessed to be supported by my parents, Fiona Mackey and
Beraldo Lilli, and my partner Aylah West, assisting with editing, proofing and motivation.

vi

Contents
Abstract

iv

List of Abbreviations and Definitions
1 Introduction
1.1 Cancer in Australia . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.1.1 Liver Cancer . . . . . . . . . . . . . . . . . . . . . . . . . .
1.2 Molecular Radiation Therapy . . . . . . . . . . . . . . . . . . . . .
1.2.1 Trans-arterial Radioembolisation . . . . . . . . . . . . . . .
1.2.2 Dosimetry in Molecular Radiation Therapy . . . . . . . . . .
1.3 The ICRP and the evolution of computational phantoms for radiation
protection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.3.1 ICRP 110 voxelised phantom . . . . . . . . . . . . . . . . .
1.3.2 ICRP 145 mesh-type phantom . . . . . . . . . . . . . . . . .
1.3.3 Phantom Evolution . . . . . . . . . . . . . . . . . . . . . . .
1.4 Geant4/GATE Monte Carlo tool . . . . . . . . . . . . . . . . . . .
1.5 Implementation of ICRP 145 phantom in
Geant4/GATE . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.6 Comparison of radiation dose to neighbouring organs from TARE .
2 Physics Principles
2.1 Radiation Dose . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2 Radionuclides and Radiopharmaceuticals . . . . . . . . . . . . . . .
2.2.1 Lutetium 177 DOTA-TATE and Lutetium 177 PSMA . . . .
2.2.2 Holmium 166 . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2.3 Yttrium-90 . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3 Internal Radiation Dosimetry . . . . . . . . . . . . . . . . . . . . .
2.3.1 MIRD Formalisation . . . . . . . . . . . . . . . . . . . . . .
2.3.2 S-values . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.4 Monte Carlo in Internal Radiation Dosimetry . . . . . . . . . . . .
2.4.1 The Monte Carlo Method . . . . . . . . . . . . . . . . . . .
2.4.2 Transport of Charged Particles . . . . . . . . . . . . . . . .
2.4.3 The Monte Carlo Method in Internal Radiation Dosimetry
[EGSnrc, Geant4, MCNP] . . . . . . . . . . . . . . . . . . .
2.4.4 GATE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

vii

xiii

.
.
.
.
.

1
1
3
3
4
4

.
.
.
.
.

6
7
7
9
9

. 10
. 10

.
.
.
.
.
.
.
.
.
.
.

11
11
12
13
13
15
15
17
18
19
19
19

. 21
. 22

CONTENTS
3 Method and Materials
3.1 Adult Voxel Reference Computational Phantoms . . . . . . . . . .
3.2 Adult Mesh-type Reference Computational
Phantoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3 Implementation of voxel phantom in GATE . . . . . . . . . . . .
3.4 Implementation of mesh phantom in GATE . . . . . . . . . . . .
3.5 GATE run parameters . . . . . . . . . . . . . . . . . . . . . . . .
3.6 Determination of S-values for ICRP 110 and ICRP 145 phantoms

viii
25
. . 25
.
.
.
.
.

.
.
.
.
.

26
28
30
31
31

4 Results
4.1 S-values for Liver ← Lesion . . . . . . . . . . . . . . . . . . . . . . .
4.2 S-values for Pancreas ← Lesion . . . . . . . . . . . . . . . . . . . . .
4.3 S-values for Gallbladder ← Lesion . . . . . . . . . . . . . . . . . . . .
4.4 S-values for Left lung ← Lesion . . . . . . . . . . . . . . . . . . . . .
4.5 S-values for Right lung ← Lesion . . . . . . . . . . . . . . . . . . . .
4.6 S-values for Left Kidney ← Lesion . . . . . . . . . . . . . . . . . . . .
4.7 S-values for Right Kidney ← Lesion . . . . . . . . . . . . . . . . . . .
4.8 S-values for Spleen ← Lesion . . . . . . . . . . . . . . . . . . . . . . .
4.9 S-values for all organs in ICRP 145 male
phantom for Ho-166, Lu-177 and Y-90 for 1cm diameter spherical source
4.10 Phantom Comparison . . . . . . . . . . . . . . . . . . . . . . . . . . .

34
34
37
40
43
46
49
52
55

5 Discussion

64

6 Conclusion

67

Bibliography

68

A Table of S values and Coefficients of variation

77

B Requirements of Radiopharmaceuticals

82

58
62

List of Figures
1.1
1.2
1.3
1.4
2.1
2.2
2.3
2.4
2.5
2.6
2.7
2.8
3.1
3.2
3.3
3.4

4.1
4.2
4.3
4.4
4.5
4.6
4.7

Summary of Cancer Data in Australia since 1982 [1] . . . . . . . . .
All cancers incidence counts and age-standardised rates for all persons
[1] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Male mesh-reference computational phantom (ICRP 145, 2020)[43] .
Construction Process of Liver (Yeom, 2013) [44] . . . . . . . . . . .

.

2

.
.
.

2
8
8

Lutetium-177 decay scheme [60] . . . . . . . . . . . . . . . . . . . . .
Production and decay of 166 Ho [15] . . . . . . . . . . . . . . . . . . .
Decay of 90 Y [65] . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Absorbed Fractions for different emissions [23] . . . . . . . . . . . . .
Absorbed dose delivered from source to target [4] . . . . . . . . . . .
Time to solve problem using Monte Carlo against analytic/deterministic
approaches [71] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Available Physics Processes and Models in Geant4 [72] . . . . . . . .
Structure of Gate [80] . . . . . . . . . . . . . . . . . . . . . . . . . . .

14
15
16
17
18

MHD image file of the AM ICRP 110 phantom with fiducial marker
in liver as visualised using AMIDE [83] . . . . . . . . . . . . . . . . .
Adult Female Mesh-type Reference Computational Phantom [43] . . .
Adult Male Mesh-type Reference Computational Phantom [43] . . . .
AF ICRP 145 mesh phantom world volume placement, red 3cm diameter 166 Ho source, visualised in DAWN. The dots in the phantom
show the different materials as described in the RegionAttributeTable
(Liver ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 110 Female phantom . . . . . . . . . . . . . . .
(Liver ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 110 Male phantom . . . . . . . . . . . . . . . .
(Liver ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 145 Female phantom . . . . . . . . . . . . . . .
(Liver ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . . . . .
(Pancreas ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Female phantom . . . . . . . . . . . .
(Pancreas ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Male phantom . . . . . . . . . . . . .
(Pancreas ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Female phantom . . . . . . . . . . . .

ix

20
22
24
26
27
28

32

. 35
. 35
. 36
. 36
. 37
. 38
. 38

LIST OF FIGURES
4.8
4.9
4.10
4.11
4.12
4.13
4.14
4.15
4.16
4.17
4.18
4.19
4.20
4.21
4.22
4.23
4.24
4.25
4.26
4.27
4.28
4.29
4.30
4.31

(Pancreas ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . .
(Gallbladder ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Female phantom . . . . . . . . . . . .
(Gallbladder ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Male phantom . . . . . . . . . . . . .
(Gallbladder ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Female phantom . . . . . . . . . . . .
(Gallbladder ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . .
(Left lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Female phantom . . . . . . . . . . . .
(Left lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Male phantom . . . . . . . . . . . . .
(Left lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Female phantom . . . . . . . . . . . .
(Left lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . .
(Right lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Female phantom . . . . . . . . . . . .
(Right lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Male phantom . . . . . . . . . . . . .
(Right lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . .
(Right lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . .
(Left Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Female phantom . . . . . . . . . . . .
(Left Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Male phantom . . . . . . . . . . . . .
(Left Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . .
(Left Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . .
(Right Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho166 and Lu-177 in the ICRP 110 Female phantom . . . . . . . . . .
(Right Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho166 and Lu-177 in the ICRP 110 Male phantom . . . . . . . . . . .
(Right Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho166 and Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . .
(Right Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho166 and Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . .
(Spleen ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 110 Female phantom . . . . . . . . . . . . . . .
(Spleen ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 110 Male phantom . . . . . . . . . . . . . . . .
(Spleen ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . . . . .

x

. 39
. 40
. 41
. 41
. 42
. 43
. 44
. 44
. 45
. 46
. 47
. 47
. 48
. 49
. 50
. 50
. 51
. 52
. 53
. 53
. 54
. 55
. 56
. 56

LIST OF FIGURES
4.32 (Spleen ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 145 Male phantom . . . . . . . . . . . . . . . . .
4.33 S-value (Organs ← Lesion) ICRP 145 Male Ho-166 1cm . . . . . . . .
4.34 S-value (Organs ← Lesion) ICRP 145 Male Lu-177 1cm . . . . . . . .
4.35 S-value (Organs ← Lesion) ICRP 145 Male Y-90 1cm . . . . . . . . .
4.36 S-value (Liver ← Lesion) for ICRP 110 and 145 phantoms, using four
different sized Holmium-166 spherical sources . . . . . . . . . . . . .
4.37 S-value (Liver ← Lesion) for ICRP 110 and 145 phantoms, using four
different sized Holmium-166 spherical sources with no mass dependence

xi

57
59
60
61
62
63

List of Tables
1.1
1.2

Characteristics of Sir-Spheres® & TheraSphere® [21] . . . . . . . . . 5
Properties of three common radionuclides for TARE [16] . . . . . . . 10

2.1
2.2

Radiation weighting factors [4] . . . . . . . . . . . . . . . . . . . . . . 11
Neutron Radiation Weighting Factors [4] . . . . . . . . . . . . . . . . 12

3.1

Main Characteristics of male and female reference computational
phantoms [33] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

4.1

Liver mass and volume for ICRP 110 and 145 phantoms [33], [43] . . 62

A.1 ICRP 110 Female (AF) S values and Coefficient of variations. For a
spherical lesion located in the liver ranging in diameter from 0.1cm
to 3cm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A.2 ICRP 110 Male (AM) S values and Coefficient of variations. For a
spherical lesion located in the liver ranging in diameter from 0.1cm
to 3cm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A.3 ICRP 145 Female (AF) S values and Coefficient of variations. For a
spherical lesion located in the liver ranging in diameter from 0.1cm
to 3cm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A.4 ICRP 145 Male (AM) S values and Coefficient of variations. For a
spherical lesion located in the liver ranging in diameter from 0.1cm
to 3cm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

xii

. 78

. 79

. 80

. 81

List of Abbreviations and
Definitions
AF
- Absorbed Fraction
AIHW
- Australian Institute of Health and Welfare
ALARA
- As low as reasonably achievable
CSFA
- Carrier-free Specific Activity
CT
- Computed Tomography
DAWN
- Data Analysis WorkbeNch
DC
- Dose Coefficient
EC
- Electron Capture
EGSnrc
- Electron gamma shower
EM
- Electromagnetic
GATE
- Geant4 Application for Tomographic Emission
Geant4
- Geometry and Tracking
HCC
- Hepatocellular Carcinoma
ICRP
- International Commission on Radiological Protection
ICRU
- International Commission on Radiation Units and Measurements
LET
- Linear Energy Transfer
MCNP
- Monte Carlo N-Particle
MIRD
- Medical Internal Radiation Dose
MRCP
- Mesh-reference Computational Phantom
NURBS
- Non-uniform rational B-spline
PET
- Positron Emission Tomography
PM
- Polgyon Mesh
PSMA
- Prostate-specific membrane antigen
RBM
- Red Bone Marrow
SAF
- Specific Absorbed Fraction
SPECT
- Single Photon Emission Computed Tomography
S-value
- Mean absorbed dose to a target organ t per unit of cumulated activity in a source region s
TACE
- Trans-arterial Chemoembolisation
TARE
- Trans-arterial Radioembolisation
TM
- Tetrahedral Mesh
YBM
- Yellow Bone Marrow

xiii

Chapter 1
Introduction
1.1

Cancer in Australia

Cancer is a disease where tissue with compromised cell growth and cell division invades other nearby tissue. These cancerous cells have originated from one or more
cells that had sustained some damage which did not lead to cell death but to an
abnormal cell growth giving the cells the ability to spread.
Cancer is still a significant cause of disease and death in the world. In Australia, data
recorded by the Australian Institute of Health and Welfare (AIHW), reports that
between 2017 and 2021 there was an estimated seven hundred thousand Australians
that were diagnosed with a form of cancer [1]. Thanks to a better understanding
of the disease and to new treatment regiments, in 2019 7 cancer patients out of 10
survived at least 5 years post diagnosis, up from 5 in 10 patients 30 years earlier
[2]. This is also reflected in a decreasing mortality rate, with only 3 in 10 deaths
in Australia due to cancer, and a decrease in the incidence rate since 2008 as summarised in cancer statistics from 1982, in Figure 1.1 [1]. This trend is also observed
in Figure 1.2, where the actual rate and projected rate has decreased since 2008,
despite the number of cases increasing over time [1].
The decrease in mortality rates in Australia can be accounted for by the use of
radiation therapy (external beam and radionuclide) for the treatment of cancer.
Radiotherapy kills cancer by damaging the DNA strand in the cancer. Some radiation directly breaks the DNA strand (direct damage) but most cell death results
from indirect damage from hydroxyl free radicals being produced (OH − ) and these
cause DNA breaks. According to literature, if two base pairs are broken within a
distance of four base pairs of each other they are unlikely to repair and cell death occurs [3]. External beam radiotherapy utilises electrons, photons, protons and heavy
ions. These are delivered to the tumour volume, and can be used in conjunction with
surgery to either shrink the tumour volume prior to surgery or kill the cancerous
cells post surgery. These particles will interact with the tumorous cells in different
manners based on their linear energy transfer (LET). High LET radiation will deposit a large amount of energy in a short range, whilst a low LET will deposit less
energy in the same range [4]. This is a consideration for radiotherapy (external beam
and radionuclide therapy) as alpha particles have the highest LET, and in turn will
1
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2

deposit the most dose (and therefore largest biological damage) to tumorous cells.
The other form of radiotherapy is internal radiation, utilising radioactive sources
secured in seeds which are directly implanted into the tumour volume (Brachytherapy) or sources chelated to pharmaceuticals [5]. These radiopharmaceuticals can
systemically target metastatic cancers in the body.

Figure 1.1: Summary of Cancer Data in Australia since 1982 [1]

Figure 1.2: All cancers incidence counts and age-standardised rates for all
persons [1]
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1.1.1

3

Liver Cancer

Liver cancer shows primarily as a malignant tumour and is often found in patients
suffering from a pre-existing liver disease [6]. Liver cancer has a much larger incidence in men (13.2 males per 100 000 individuals compared to 4.3 females) [2], and
has the poorest survival rate (19%) of the most commonly diagnosed cancers in men,
due to other underlying health conditions that are often associated with the disease
[7]. The primary form of liver cancer is hepatocellular carcinoma (HCC), with liver
cancer being the leading cause of cancer death globally [8]. Computed tomography
(CT) is the method of choice for the diagnosis of HCC, with the use of pre-contrast
and three post-contrast (late hepatic, arterial and delayed) image to visualise HCC.
CT has excellent sensitivity for lesions greater than 2cm, with sensitivity reducing
with reduced lesion size [8]. For patients diagnosed, HCC is surveyed using ultrasounds in conjunction with the monitoring of a serum marker (α-fetoprotein)[8].
Australia’s management works on a curative where possible basis, often resulting
in surgical and non-ablative therapies. The most common non-ablative therapy
is transarterial chemoembolisation (TACE), where chemotherapy and embolic substances are injected through the hepatic artery. Hepatic carcinomas are supplied
through this arterial branch, with this method providing a 75-80% disease control
rate in support with surgical therapies [9]. Transarterial radioembolisation (TARE)
utilises radioembolisation with the selective delivery of radionuclides, usually the
pure beta emitting Yttrium-90, to primary or metastatic liver cancer via radiolabeled beads. This has been shown to result in longer time to progression and lower
toxicity than conventional chemotherapy treatments [10]. TARE is mostly used in
intermediate or locally advanced HCC cases, with the radiation treatment allowing
for surgical responses [8].

1.2

Molecular Radiation Therapy

Radiation emitted by radioactive isotopes can be exploited to cause damage to cells.
These radionuclides can be attached to drugs that can target specific cellular receptors expressed mainly in diseased (cancerous) cells, minimizing uptake in healthy
tissue [11]. The treatment of benign or malignant diseases with the use of internally
distributed radionuclides is called Molecular Radiation Therapy (MRT).
The ability to selectively deliver radiation dose to targeted cells whilst sparing
healthy tissue is one of the advantages of MRT over other treatments. In fact,
MRT is an effective method to target metastatic cancer cells [12]. Moreover, the
choice of short range beta or of alpha emitting radionuclides ensures minimizing the
radiation dose to healthy surrounding or neighbouring tissue.
The radiation dose delivered by the radiopharmaceutical is determined by its pharmacokinetics, which describes how the radionuclide moves between tissues and organs as a function of time [13]. The pharmacokinetics of the radiopharmaceutical
differs in each individual and information on the radiopharmaceutical’s pharmacokinetics can be obtained by administering radionuclides that can emit also photons of
a useful imaging energy (between 80 and 400 keV) [14].

CHAPTER 1. INTRODUCTION

4

Ideal radionuclides for MRT emit short range particles, such as beta or alpha particles, so to deposit most of their energy locally, they have a half-life of the order
of days to maximise the time the therapy is given without having long term effect
and, potentially, emit photons of energies that can be imaged using a SPECT or a
PET camera. Radionuclides such as Lutetium-177 (gamma emissions at 112 keV
and 208 keV), Yttrium-90 (positron emission at 936 keV) or Holmium-166 (gamma
emission at 83 keV) meet these criteria [11],[15].

1.2.1

Trans-arterial Radioembolisation

One of the strategies to manage cancer is to cut off its blood supply (embolisation) so to starve the cells of oxygen and nutrients. Trans-arterial radioembolisation
(TARE) achieves this by injecting embolisation agents labelled with radionuclides
into the arterial blood supply [16]. An established application of this technique is
the trans-arterial embolisation of liver cancer [17] with microspheres labelled with
the pure beta emitter Y-90. The microspheres will lodge into the small vessels of
the tumour where they will emit radiation. The β − particles have a short range
(millimetres) and will deposit their energy in the tissue.
This method generates a large dose level to tumour, by injecting the spheres through
a catheter, the cancer draws upon hepatic arterial blood while the portal vein provides the main blood supply for healthy liver tissue [18]. 1 GBq of Y-90 labelled
microspheres will deposit 50Gy/kg to the patient [17]. There are two commercially
available spheres which are commonly used for radioembolisation; the glass based
TheraSphere®
(https://www.bostonscientific.com) and the resin based SIR-Sphere® (https://www.
sirtex.com/us/). The TheraSphere® (MDS Nordion, Ottawa, Canada) uses a nonbiodegradable glass sphere, ranging from 20-30 microns in diameter with each micron
holding an activity of 2500 Becquerel at time of calibration [18]. This varies slightly
to the SIR-Sphere® (Sirtex, Lane Cove, Australia) which utilises a biodegradable
resin sphere. The resin has a lower density than the glass sphere however is slightly
larger (20-60 microns in diameter) and is beneficial for patients with metastatic cancers in the liver. These spheres each contain a specific activity of 50 Bq at the time
of calibration. Both these spheres are valuable for treating liver tumours which are
inoperable, with a minimal level of invasion required whilst delivering a high dose
of radiation to the targeted area. A difference between the resin and glass spheres
is the type of distribution throughout the liver, the glass spheres homogeneously
distributed while the resin spheres are heterogeneously distributed [19]. Table 1.1
describes the characteristics of each of these microspheres, however Sangro et. al.,
[20] demonstrates the equivalence for the use of either microsphere.

1.2.2

Dosimetry in Molecular Radiation Therapy

In radiation therapy, it is important to be able to assess the radiation dose imparted
to the diseased cells and to healthy tissue. The methodology to estimate dose in
MRT is discussed in chapter 2 (Section 2.3), in summary knowledge of the type of
emission, energy of emitted particles and location of the radionuclide in the body is
required, together with information on the time the radionuclide will spend in each
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Diameters (µm)
Specific weight (g/dL)
Activity per microsphere to date calibration (Bq)
Number of microsphere (vial, million)
Material
Activity in the vial (GBq)

5
Sir-Spheres®
32 ± 10
1.6
50
40-80
Resin
3 ± 10%

TheraSphere®
22 ± 10
3.6
2500
1.2-8
Glass
3,5,7,10,15 or 20

Table 1.1: Characteristics of Sir-Spheres® & TheraSphere® [21]

organ or tissue as this will determine how many particles and how much energy has
been released by the radionuclide.
In MRT, radionuclides are chosen so that most of the energy released is deposited
close to the position of emission, however some dose will be deposited further away
from where the radiopharmaceutical has been taken up, this can lead to radiation
dose to healthy tissue. However, radiation dose to healthy tissue is also due to the
radiopharmaceutical taken up in the healthy tissue itself. An example is the radiation dose to kidneys due to radiopharmaceutical clearance from Y-90 microsphere
therapy.
In trans-arterial radioembolisation, the local administration of the radiopharmaceutical, via the blood supply, highly reduces the possibility of the radiopharmaceutical
to redistribute throughout the patient’s body. Radiation dose to neighbouring organs will be mainly due to emitted particles (photons or beta electrons) that have
enough energy to travel the distance [16].
Computational models of the uptake of radiopharmaceuticals in patients offer a flexible tool to investigate radiation dose to organs and tissues from Molecular Radiation
Therapy. These phantoms are analytical, voxelised or tetrahedral representation of
standard adult or children population [22] and allow radiation dose estimation when
implemented in Monte Carlo codes.
Dosimetry refers to the determination of energy deposition in tissue through the
use of measurements and calculations. In most cases, patients are administered
the same activity on each therapy cycle, and will often not consider the variations
in metabolic clearance or uptake of a radiopharmaceutical in different individuals.
MIRD pamphlet 21 [23] outlines a general guideline for dose estimation whilst MIRD
pamphlet 23 provides best-practice SPECT guidance for radionuclide dosimetry [24],
however it is demonstrated in Strigari et al., [25] that 48 of 79 studies demonstrated
an absorbed radiation dose-effect in MRT. The study suggests ’dosimetry-based personalised treatments would improve outcome and increase survival’ as well as tissue
toxicity [25]. This personalised dosimetry is time consuming and must be obtained
from quantitative imaging studies for the patient [26].
Despite the general guidelines supplied by MIRD, there still exists a large amount
of variation in dosimetry measurements. Uribe et al., [27] took 119 submissions that
were asked to present details and results from a 177 Lu dosimetry challenge designed
by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Of the sub-
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missions, 60% used voxelised dose methods, with 47% of those being commercially
available software. In these voxelised results, organ volumes differed up to 49.8%
whilst lesion’s volumes showed a max difference of 176%. With computational calculations, an important consideration is also the time to complete computations,
in which the median segmentation time was 43 minutes and total simulation time
was 89 minutes [27]. This variability demonstrates the need for a standardised
method and procedure for the determination of nuclear medicine dosimetric calculations. Mattsson et al., also discusses the need for a review of radiopharmaceutical
bio-kinetic data, with some radiopharmaceutical data being more than 20 years
old [28],[29]. As computing processes have improved, there is a need for the reassessment of these for a more accurate representation of the biokinetic processes
through the body. The limited number of subjects per study in both genders and
varying ages has generated a lack of representation in some categories [28].
In order to improve dosimetric calculations (rather than have radiation-absorbed
dose derived from models and bio-kinetics) internal dosimetry programs have been
developed. IDAC-Dose2.1 was developed based on the ICRP133 publication [30].
The program calls from the ICRP107 decay database [31], considering 83 different
source regions and irradiating 47 target tissues [32]. IDAC was validated against
the ICRP dosimetry program, Dose and Risk calculation (DCAL) and employs the
same computational framework. IDAC-Dose2.1 has a sub-module for absorbed dose
estimates in radiopharmaceutical therapy [32]. IDAC-Dose2.1 also calculated absorbed doses in spherical structures 1mm to 9cm in diameter.

1.3

The ICRP and the evolution of computational
phantoms for radiation protection

The International Commission on Radiological Protection (ICRP) is an independent,
international organisation that is the primary body in the protection of people, animals and the environment from ionising radiation [33]. In order to protect people
from ionising radiation, the commission has used, and published information on,
computational phantoms that, implemented into radiation transport Monte Carlo
codes, allow to investigate radiation risks to the population. In 2009, the ICRP
presented a voxelised computational phantom of the reference male and female [33],
these computational phantoms can be and have been used for the assessment of radiation dose for medical use, such as external radiation beam therapy or molecular
radiation therapy.
Before the development of voxelised computational phantoms, mathematical models
were utilised to determined dosimetric quantity such as Specific Absorbed Fractions
or S-values (see Chapter 2.4.1-3). These phantoms have evolved into voxelised phantoms, such as the ICRP 110 phantoms, based on magnetic resonance and computed
tomographic models of the human body, and then into Adult Mesh-type reference
computational phantoms. In voxel phantoms, slice thickness is in the order of a few
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millimetres, which is insufficient for calculating dose to areas of the body such as
the eye lens, the skin, and organ walls [34]. One of the advantages of the new ICRP
145 phantoms, with its polygon mesh, is to allow dosimetric calculations that are
closer matched to individuals, improving safety and accuracy [34].

1.3.1

ICRP 110 voxelised phantom

The voxelised adult male and adult female reference phantoms, originally published
in ICRP’s 2007 recommendations [35], are based on the anatomical parameters
published in ICRP’s 2002 publication [36]. At the time, the best methodology was
the use of voxels to define organs and tissues. These voxel phantoms are based
on high-resolution scans of male and female patients, if a male or female phantom
was required, the voxel dimensions needed to be altered account for different organ
dimensions and masses for males and females. The difference in the number of voxels
(approx. 2 million for males and 4 million for females) lead to a discrepancy in the
resolution of the two phantoms. However, despite improvements to the models based
on the GSF Munich voxel phantoms [37, 38], there are still limitations to the voxel
models for respiratory and alimentary tracts, as well as the difficulty in deforming
the phantoms for paediatric patients. These phantoms have been developed from
CT high-resolution scans of a male and female patient, which information allowed a
spatial resolution of 2.137 x 2.137 x 8 mm3 for the male phantom and 1.775 x 1.775
x 4.8 mm3 for the female phantom [33]. The voxelised models are limited by the
low spatial resolution as some tissues were not possible to be segmented directly,
e.g. the lens of the eyes, and they had to be added to the model post-segmentation.
Other organs such as the skin layer or the extra-thoracic (ET) airways had to be
represented by an entire voxel layer. Bronchioles were also not possible to segment,
and these are taken into account in the lung tissue assuming a lung density given
by the weighted average of the two tissues densities including air [39]. Moreover,
voxelised human phantoms are difficult to scale to represent the range of sizes and
shapes in the human population and between children and adults.

1.3.2

ICRP 145 mesh-type phantom

In 2018, mesh-type reference phantoms (MRCP) were generated from the ICRP
110 voxelised phantoms using a TetGen formatting program [40], Figure 1.3. The
majority of the structures were implemented directly through conversion of the voxel
phantom to the polygon-surface phantom using 3D-DOCTOR (Able Software Corp.,
Lexington, MA) [41]. Figure 1.4, reproduced from the conversion of the voxelised
liver to the polygon-surface [42], summarises the process of converting and refining
the conversion of a voxelised liver to a polygon-surface and then modifying the
volumes to match the liver mass [36].
More complex organs, such as the large intestine, required the use of the nonuniform rational B-spline (NURBS) format; the small intestine was developed using
a simple pipe model [45]. Other complex anatomical features (skull, ribs and spine),
were generated using a well-defined model adjusted three-dimensionally to match
the ICRP reference phantoms [43]. So in order to handle the NURBS or mesh-based
phantoms, the development of Monte Carlo methods has been at the forefront of
research [46], [47] and led to the development of programs such as GATE.
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Figure 1.3: Male mesh-reference computational phantom (ICRP 145, 2020)[43]

Figure 1.4: Construction Process of Liver (Yeom, 2013) [44]

One of the advantages of the new mesh phantom is the ability to simulate thin
surfaces or tracts. This, in particular, allows the definition of a continuous skin
layer of 50 µm thickness as target regions so that radiation dose to cells at risk in
the skin can be assessed. The ICRP 145 phantoms are covered by a continuous,
thin skin layer, rather than the voxel layer around the ICRP 110 phantom. Similar
techniques have been used to define thin tissue structures such as the stomach, the
oesophagus or the urinary bladder wall. Another major improvement with respect
to the ICRP 110 phantom is the refined modelling of the major blood vessels, which
were segmented in the ICRP 110 with loss of resolution, and the implementation
of small blood vessels joined to the major blood vessels. However, the intra-organ
vasculature is still not modelled.

CHAPTER 1. INTRODUCTION

1.3.3

9

Phantom Evolution

In order to obtain general dose estimates, simulations are conducted on computational phantoms. Human computational phantoms have developed substantially
over the last 50 years as computing power has increased. Phantoms began using
mathematical equations to generate solid geometric objects which could define different shapes whilst generating boundaries (ORNL, MIRD) and has been the basis
for many reference dose and risk coefficients [48]. These are useful for morphing to
represent paediatric models, however are very poor in representing realistic anatomy.
Phantoms then developed into voxel phantoms, where the phantom was derived from
a 3D array of voxels, with each voxel representing a specific organ (includes elemental composition and density). The voxels are generated through segmentation of
individual image slices from a CT or MR scan, and provide a high level of realism
[48]. However, the voxels are poor for morphing of body sizes, due to the alteration
of voxel size and composition and morphing occurs. In order to generate accurate phantoms for different patients (adult male, adult female, child, baby) CT/MR
scans would be required with each requiring segmentation. The most recent computational phantom is the hybrid or mesh phantom, as they are a combination of
the realism of voxel anatomy and the flexibility of the mathematical models. These
phantoms are generated using CT/MR scans, and generating a 3D rendering of the
subject anatomy. The mesh phantoms are advantageous over the prior models as
they have correct spatial anatomy (unlike mathematical) and have a continuous and
smooth rendering in all directions (unlike voxels) [48]. 3D rendering software also
allows for the ability of developers to reshape surface in the anatomy, seen in the
3D-DOCTOR, where individual regions of polygon mesh can be adjusted inwards
or outwards. These phantoms are valuable for defining dose and risk coefficients,
however are limited in individual patient dosimetry. As each patient will react differently to radiation (stochastic effects), and the inability to correctly morph the
phantom to individual patients (down to correct organ size and mass), individual
patient dosimetry is not recommended.

1.4

Geant4/GATE Monte Carlo tool

GATE (Geant4 Application for Tomographic Emission) is an implementation of the
Monte Carlo simulation toolkit Geant4 [49], and was developed for the investigation
of nuclear medicine SPECT and PET imaging [50]. GATE uses a macro language
to define complex geometry, the particle source, and the physics of the Monte Carlo
simulation, making use of the very well established and validated Geant4 C++
classes. Moreover, it can handle tetrahedral mesh geometries as well as the energy
deposited within these geometries. The established nature of Geant4 physics, and
the ability of GATE to generate complex geometries made the use of GATE suitable
for this study.
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Implementation of ICRP 145 phantom in
Geant4/GATE

The aim of this project was to implement the ICRP 145 mesh-reference phantom in
the Geant4/GATE Monte Carlo tool. Radiation doses to organs from the distributions of Holmium-166, Lutetium-177 and Yttrium-90 in a spherical hepatic lesion
have been compared with radiation doses estimated using the voxelised ICRP 110
phantom. These radionuclides have been chosen to investigate their impact on radiation dose to healthy surrounding organs when used in hepatic radioembolization
using microspheres. The S-values, a measure of the mean absorbed dose to the
kidneys, pancreas and lungs, per unit of cumulated activity in the liver, have been
determined for these radionuclides. These results allow for comparison between the
two phantoms for internal dosimetry measurements, as well as the three radionuclides for their use in nuclear medicine.

1.6

Comparison of radiation dose to neighbouring
organs from TARE

Table 1.1 shows the physical characteristics of the three radionuclides investigated in
this project. These radionuclides are suitable for TARE, as they are primarily beta
emitters (166 Ho and 177 Lu have low energy gamma emission) and have a short range
in tissue [51], [52], [53]. As shown in Table 1.2, 166 Ho and 177 Lu have low energy
gamma emissions which has the advantage of being utilised for SPECT imaging [16].
These radionuclides can be injected as loaded microspheres (see Chapter 2.3.3), and
have a homogenous distribution throughout the tumour.
Radionuclide

Half-life (t1/2 )

EβM ax (MeV, %)

Eγ (keV, %)

90

64.1 h

2.284 (99.9)
1.854 (48.8)
1.774 (49.9)

Nil

Maximum Tissue
Penetration Range (mm)
11

81 (6.6)

8.7

113 (6.6)
208 (11)

2.2

Y

166

Ho

26.8 h

177

Lu

6.716 days

0.497 (78.6)

Table 1.2: Properties of three common radionuclides for TARE [16]

Chapter 2
Physics Principles
2.1

Radiation Dose

Radiation dose (or absorbed dose), D is the mean energy of ionising radiation (d˜)
deposited in an absorber per mass (dm). Radiation dose has units of J kg−1 , or gray
(Gy). This measurement does not take into account the type of ionising radiation.
d˜
(2.1)
dm
Equivalent dose, indicated by HT takes into account relative biological damage
caused by radiation interacting with a particular tissue or organ [4]. The biological
damage caused to different organs is due to the different level of sensitivity in organs,
due to density. The equivalent dose depends on the type and the energy of the
radiation. It’s unit of measurement is the sievert (Sv) and is given by;
D=

HT = ΣR DT,R × wR

(2.2)

where DT is the averaged absorbed dose in tissue T, and wR is the radiation weighting factor. Table 2.2 shows different weighting values for different radiation types.
Type of Radiation
x-rays
γ-rays
Electrons, Positrons
Neutrons
Protons >2MeV
α particles, fission
fragments, heavy ions

Radiation Weighting Factor (wR )
1
1
1
Continuous function of neutron energy (see below)
2
20

Table 2.1: Radiation weighting factors [4]

For neutron radiation weighting factors, the weighting factor depends on the
neutron energy.
The effective dose, E is the sum of all the organ equivalent doses. This differs
from the whole body dose as the effective dose characterises the non-uniformity of
11
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En < 1M eV
1M eV ≤ En ≤ 50M eV
En > 50M eV

12
2

2.5 + 18.2e−[ln(En ] /6
2
5.0 + 17.0e−[ln(2En ] /6
2
2.5 + 3.25e−[ln(0.04En ] /6

Table 2.2: Neutron Radiation Weighting Factors [4]

organ dose distribution. This results in a single value which takes the non-uniformity
and dosage to each organ. This was originally used to estimate radiation risk to
workers, but is now utilised in nuclear medicine studies. Effective dose has units of
sieverts and is calculated by;
E = ΣT wT × DT × wR = ΣT wT × HT

(2.3)

where DT is the average absorbed dose in organ T, wT is the tissue weighted factor for
organ T and wR is the radiation weighting factor depending on the type of radiation.
The only downside to the effective dose measurement is that the calculations are
based on the average human. The tissue weighting factor was defined in the ICRP
Publication 60 [54] as the ratio of the whole-body dose, which would cause a certain
probability of cancer induction to the absorbed dose in that organ [55]. This was
superseded by the ICRP 103 Publication [35]. It is also important to note that tissue
radio-sensitivity is age dependent, so despite reference phantoms being available for
practitioners, this must be considered.

2.2

Radionuclides and Radiopharmaceuticals

A radiopharmaceutical is a pharmaceutical substance with a radioactive isotope
attached which can be used for diagnostic or therapeutic purposes. These radiolabelled drugs are designed based on specificity, selectivity and affinity (the chemical
forces that cause the drug to associate with the receptor/enzyme) for specific targets
[56], [4]. These in conjunction with the pharmokinetics, metabolic profile and the
physico-chemical properties of the radionuclide determine a radiopharmaceutical’s
efficacy [57]. Appendix B outlines the full requirements for the use of radiopharmaceuticals clinically.
Radiopharmaceuticals require specific considerations for different applications. This
includes the type and energy of emissions, which determine the availability of useful
photons or gamma-rays for counting. Energies of 50-600 keV are useful for external
detection as energies below this are highly likely to be absorbed in the body and
won’t be detected. This also increases dose to patients without providing useful
information to practitioners. Finally, the physical half life of the radionuclide needs
to be within the range of seconds to days (preferably minutes to hours), to allow for
preparation, injection, biodistribution and imaging of the radiopharmaceutical. It
is important that the half life is not extensively long, as a large part of the radiation
dose will be deposited to the patient after the imaging procedure has been carried
out.
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Lutetium 177 DOTA-TATE and Lutetium 177 PSMA

Lutetium 177 has a half life of 6.716 days and decays via β − and γ radiation. As
seen in Figure 2.1, Eβ(max) is 497 keV and has a probability of occurring for 78.6%
of decays. Beta emissions also occur at 384 keV (9.1%) and 176 keV (12.2%), whilst
low-energy gamma photons are emitted at 113 keV (6.6%) and 208 keV (11%) [58].
The beta particles have a mean penetration range of 670 µm, making it ideal for
small tumour volumes and for sparing healthy surrounding tissue [11].
Lutetium 177 (177 Lu) is a therapeutic radionuclide which is used primarily for the
treatment of Somatostatin Receptor (SSTR) expressing neuroendocrine tumours
that metastasise amongst the liver. Lutetium-177 when used in conjunction with
the pharmaceutical, DOTA-octreotate (DOTA-TATE), to treat these SSTR neuroendocrine tumours [51]. This use of Lutetium-177 in peptide receptor-targeted
radionuclide therapy (PRRT) with DOTA-TATE has also allowed for treatment of
inoperable neuroendocrine tumours (NETs). Lutetium-177 has more recently been
used with prostate-specific membrane antigen (PSMA) which appears in mainly the
prostate, as well as in the kidney, lacrimal-, parotid- and sub-mandibular-glands
[11]. The radionuclide undergoes β emission for a short range, useful for treatment,
while the γ emissions making it useful for imaging.
Lutetium attached to PSMA is a viable option for treatment of metastatic prostate
cancer following initial chemotherapy or radiotherapy. PSMA is a glycoprotein which
is found in low levels in the prostate, however is largely found in prostate cancers
(increased by up to 1000%) [11]. PSMA receptors have a process in which proteins
bind to the cell, allowing for uptake of PSMA labelled radioisotopes in the tumour
volume. However there are PSMA receptors present in other organs (small intestine,
renal tubules) which results in some uptake in healthy tissue.

By the injection of Lutetium-177 labelled radiopharmaceuticals through the
right or left hepatic artery, there is an increased uptake by the metastases in the
liver. 177 Lu radiopharmaceuticals have preferable physical attributes when compared to similar radioisotopes such as Yttrium-90 (90 Y) . Yttrium-90 is discussed in
depth in Section 2.2.3, however, Yttrium-90 has a larger Eβ(max) of 2.28 MeV and
therefore an increased range (12 mm) when compared to Lutetium-177 [11]. Therefore, the dose deposited is more localised, making it valuable for receptor-targeted
radionuclide therapy [58], [59].

2.2.2

Holmium 166

Holmium 166 (166 Ho) is a radionuclide that can be utilised in the treatment and
imaging of liver cancer and liver metastases. Holmium 166 has a half-life of approximately 26.8 hours, and emits beta and gamma radiation. The most attractive
component of holmium is that the high energy beta emissions are useful for therapeutic requirements, while the gamma radiation is useful for nuclear medicine imaging
(SPECT), as well as Magnetic Resonance Imaging (MRI) due to its paramagnetic
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Figure 2.1: Lutetium-177 decay scheme [60]

nature.
Holmium-166 can be produced by two methods, the first is through the neutron activation of 165 Ho in a nuclear reactor, Holmium-164 has a natural abundance of 100%,
and can be activated by a neutron to form a highly pure 166 Ho isotope [15]. However, a part by-product (7 × 106 smaller by product) is the metastable 166m Ho. The
metastable Holmium has a half life of 1200 years and similarly emits beta and gamma
radiation. The production of the unstable holmium however is far more likely, as
the cross section for thermal neutron activated holmium-166 (165 Ho(n, γ)166 Ho) is
64 barn compared to 3.4 barn for the production of the metastable holmium-166
(165 Ho(n, γ)166m Ho) [61].
The second production method is through the neutron activation of dysprosium164. Similarly to the previous method, 164 Dy is activated by two neutrons (2n, γ) to
form the 166 Dy isotope [62]. The radionuclide undergoes beta decay with a half-life
of 81.5 hours to produce 166 Ho. The main benefit to this method is the carrier-free
production of Holmium-166, having no metastable holmium production.
Figure 2.2 shows the the two methods for the production of 166 Ho, as well as
its decay scheme. It emits 1774 and 1854 keV (49.9% and 48.8% yields respectively) beta particles as well as 80 and 1379 keV (6.7% and 0.9% yields respectively)
gamma rays. One major advantage Holmium-166 has is its 26.8 hour half life [15],
means that more than 90% of the dose will be deposited in the first 4 hours, giving
practitioners enough time to image or treat the patient, and the dose is kept to a
minimum. This half life compared to a similar alternative, Yttrium-90 (90 Y) with a
half-life of 64.6 hours, will deposit dose for a longer time.
Holmium has applications for imaging and treatment in the liver using selective
internal radiotherapy (SIRT) [63]. Holmium labelled micro-spheres (30 µm diameter) are administered through the hepatic artery and are carried to the target lesion
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[61]. Liver tumours are dependent upon the hepatic artery for blood supply, meaning the micro-spheres are carried directly to the tumour, sparing healthy liver tissue
(supplied by the portal vein) [8].

2.2.3

Yttrium-90

Yttrium 90 (90 Y) is a therapeutic radioisotope which emits predominantly high energy beta particles, and is commonly used in the treatment of liver metastases.
Yttrium 90 possesses a half life of 64.042 hours [64] and decays to Zirconium 90 (Zr90) in a stable ground state, Figure 2.3. The maximum particle energy emitted from
Y-90 is a 2.28 MeV beta particle with a 99.983% probability. The maximum particle
energy as well as the 0.94 MeV average energy, generates a high dose deposition in
patients from the radionuclide. When comparing the maximum energy of 177 Lu and
166
Ho, 90 Y has the largest maximum particle energy and average energy, therefore
will deposit the highest dose per Becquerel of activity. This increased energy also
allows the particles to travel further in soft tissue, with the range of beta particles
ranging from 2.5mm to 11mm [53].
Ytrrium-90 is most commonly used in radioembolisation for primary and metastatic
cancers of the liver (see Section 1.2.1).

2.3

Internal Radiation Dosimetry

Internal radiation dosimetry refers to the analysis of radiation energy deposited in
organs by internal radionuclides. Figure 2.4 demonstrates how different forms of
radiation can travel; photons have a longer path length compared to electrons, and
so we expect to see dose in organs further from the lesion. This compared to electrons which deposit their energy along a short path and so are less likely to deposit
dose in organs outside the source. It is important to note that radiation will not be
entirely confined to the source for electrons. To ensure the patient is safe and dose
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to healthy organs is minimised, phantoms studies of internal dosimetry is vital to
nuclear medicine and patient safety.
In nuclear medicine, the delivery of radiopharmaceuticals, the activity administered
to the patient, the radionuclide itself, pharmokinetics and the disease of the patient
all play a role in dose calculations. The calculation of internal dosimetric values
can be achieved using the MIRD scheme (from the Medical Internal Radiation Dose
Committee of the Society of Nuclear Medicine). The MIRD scheme has received
a larger acceptance within the nuclear medicine community for performing these
internal dosimetry measurements [4]. This method takes into account the activity
of the radionuclide, the energy emission and intensity of these emissions, and the
dose which is absorbed dose measured.
The internal dosimetry calculations rely upon the physical, biological and effective
half-lives of the radiopharmaceutical. The physical half-life (Tp ) refers to the time
taken for half of the atoms in the unstable nuclei to become stable. The biological
half-life (Tb ) is the time to eliminate, by natural processes, half the amount of material. The effective half-life (Tc ) is the quantity which includes both the physical,
and biological half-lives:
1
1
1
=
+
(2.4)
Tc
Tb Tp
In the MIRD scheme, a source organ is an organ which has radioactive source uptake, and a target organ has dose incident onto it from the source organs. However,
a major contributor to dose is the self-dose, which describes radiation dose to an
organ which is from the radionuclide within the organ. In order to determine the
radiation dose from a source to a target organ the amount of activity in the source
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Figure 2.4: Absorbed Fractions for different emissions [23]

and all the relevant half-lives must be taken into account [4]. The self-dose, and the
emission of radiation from the target to source also depends on the type of emission
as seen in Figure 2.4.
The time integrated activity, Ã is a product of the amount of radiation activity
in the source organ and the length of time the activity is present. It has units of
Becquerel seconds (Bq ·sec) and we can describe the time integrated activity as a
time activity curve;
Z
TD

Ã(rs , TD ) =

A(rs , t)dt

(2.5)

0

In equation 3.2, rs is the position where source s of activity A is located, while TD
is the time period to integrate over [23].

2.3.1

MIRD Formalisation

The MIRD formalisation was established by a committee subset of the Society of Nuclear Medicine. The group aimed to provide a guideline for assessment of absorbed
dose to whole organs, tissue sub-regions, voxelised tissue structures and individual cellular compartments used in diagnostic and therapeutic nuclear medicine [23].
MIRD Pamphlet 21 adopts the dosimetric quantities of equivalent dose and effective
dose in evaluations of risk associated with stochastic and tissue effects.
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Figure 2.5: Absorbed dose delivered from source to target [4]

Absorbed Dose
Absorbed Dose D(rT ) is defined as the mean energy imparted on a target region rT
per unit mass of that region [66]. The time-dependent dose rate, Ḋ is given by
Ḋ(rT , t) =

X

A(rS , t)S(rT S , t)

(2.6)

rS

where A(rS , t) is the time integrated activity of a radiopharmaceutical in the source
tissue, rS . The value S(rT ← rS , t), also known as the S-value, is a radionuclidespecific quantity for the mean absorbed dose delivered to the target organ, rT at
time t per unit activity present in source organ, rS [23]. For computation phantoms,
the S-value is dependent upon the radionuclide in use, as well as the age and sex of
the anatomical model selected for use. We can also determine the mean absorbed
dose D(rT , TD ) to target tissue rT over a defined dose-integration period TD by
Z

TD

D(rT , TD ) =
Ḋ(rT , t)dt
0
X Z TD
=
Ã(rS , t)S(rT S , t)dt
rs

(2.7)

0

where TD is commonly taken to be infinite, as radionuclides used in nuclear medicine
often have a short physical half-life.

2.3.2

S-values

The S-value is the mean absorbed dose to the target organ rT per unit of cumulated
activity in the source region rS (also known as mean dose per cumulated activity)
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[67]. It has units of mGy/MBq · sec. The S-value, is specific to the radionuclide
and the computational phantom in use. This is due to the computational phantom
defining the spatial geometry and tissue compositions of rS and rT . S is given by
S(rT ← rS , t) =
=

1
M (rT , t)

X
1
Ei Yi Φ(rT ← rS , Ei , t)
M (rT , t) i
X
X
∆Φ(rT ← rS , Ei , t) =
∆i Φi
i

(2.8)

i

where Ei is the mean or individual energy of the ith nuclear transition, Yi is number
of ith nuclear transitions per nuclear transformation, ∆i is their product, φ(rT ←
rS , Ei , t) is the absorbed fraction, and M (rT , t) is the time dependent mass of the
target tissue rT [68].
The specific absorbed fraction Φ(rT ← rS , Ei , t) is defined as the ratio of the absorbed fraction and the target mass. The absorbed fraction is affected by the distance between the source and target organs as the bodies materials attenuate the
radiation [14]. For complete dosimetry measurements, the absorbed fraction must
be determined for each type of emission and for each source-target pair.

2.4
2.4.1

Monte Carlo in Internal Radiation Dosimetry
The Monte Carlo Method

The Monte Carlo method was proposed by Metropolis and Ulam in 1949 as a method
of dealing with a class of problems in mathematical physics [69]. The approach relies
on “a statistical approach to the study of differential equations, or more generally,
of integro-differential equations that occur in various branches of the natural sciences” [69]. Monte Carlo is distinctive in that it depends on random samples to
approximate deterministic quantities. As Monte Carlo is a numerical method for
solving mathematical problems, physics problems must be formulated in mathematical terms [70]. The biggest advantage of Monte Carlo comes when the complexity
of problems increase, specifically when a problem is 5 dimensions or higher [71].
This is demonstrated in Figure 2.6, where as the complexity of a problem increases
(dimensions), the time to solve the problem becomes linear compared to an exponential increase for analytic/deterministic approach. In radiation physics, problems
are generally six dimensions or higher [71] making the Monte Carlo method a useful
simulation tool for medical physicists. As Monte Carlo relies on statistical methods
including sampling and due to the complexity of radiation physics, radiation transport and the stochastic nature of radioactive decay suits the simulation.

2.4.2

Transport of Charged Particles

In radiation transport codes such as that utilising the Monte Carlo method, charged
particles play an important role. These include electrons, protons, positrons and
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Figure 2.6: Time to solve problem using Monte Carlo against
analytic/deterministic approaches [71]

some heavy ions including carbon ions. In Geant4 the transport of these particles
through the environment is a result of “Geant4 kernel’s Stepping Manager class and
the actions of processes which it invokes–physics processes and the Transportation
‘process’ which identifies the next volume boundary and also the geometrical volume
that lies behind it, when the track has reached it” [72]. Geant4 is utilised in this
study as GATEs physics processes utilised Geant4, due to being suitable in low energy physics seen in nuclear medicine. An expected length for interaction occurrence
is determined through polling the processes which apply to that step, then where
the particle interacts is determined [73]. To do this the length of interaction or the
Mean Free Path needs to be determined. In order to do this, the number of atoms
per volume needs to be determined for interaction probability;
n=

Nρ
A

(2.9)

Where N is Avogadro’s number, ρ the density of the medium, and A is the mass
of a mole. This physics is available in simple materials (body materials included).
This formula can be used for materials made of multiple elements by;
ni =

N ρwi
Ai

(2.10)

where wi is the proportion by mass of the ith element. This value, n is the number
of atoms per unit volume and is used to determine the mean free path of a process
(or interaction length) given by;
X
λ(E) = ( [ni · σ(Zi , E)])−1
i

(2.11)
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P
where σ(Zi , E) is the total cross section per atom of the process and i runs for all
elements which make up the material. The components which make up the bracket
is called the macroscopic cross section, with the inverse of this being the mean free
path.
Charged particles vary to photons in that they experience a large amount of
collisions along their path, depositing energy, before they come to their rest. These
interactions often have a minimal change in energy and direction, making it possible
to group each small interaction into a single interaction, creating a condensed history
simulation [74].

2.4.3

The Monte Carlo Method in Internal Radiation Dosimetry [EGSnrc, Geant4, MCNP]

Monte Carlo in medical physics aims to model nature through simulations that are
based on the dynamics and physical principles that exist in the system. The common
Monte Carlo simulation platform, Geant4, which is utilised by GATE, has excellent
validation in relation to its physics modelling [75]. These have been validated by
a comparison between the physics modelling in Geant4 with the real experimental data, whether at a microscopic level (thin target) or macroscopic (thick target)
[74]. The use of the Monte Carlo method has seen a drastic growth in the area
of medical physics [70]. The number of papers published in the medical physics
field utilising Monte Carlo has doubled every five years between 1967 and 2000 [76].
This covers a wide range of fields within medical physics, including testing of silicon
micro-dosimeters [77] and hadronic models in carbon ion therapy [78].
There are various Monte Carlo codes which are available to use in medical physics,
and more specifically internal radiation dosimetry. These codes and their differences
are explored in Pacilio et al., which observes the differences in MCNP4C, EGSnrc,
and GEANT4 codes through calculating S-values for voxel dosimetry. The study,
observed differences in S-values from beta emissions of radionuclides with MIRD
calculations (utilised EGS4 code) [79]. For voxel S-values, differences were noticeable in bremsstrahlung tails or when there is a large contribution from electrons less
than 500 keV [79]. Pacilio observed divergence in the bremsstrahlung region (up to
about 90% in terms of voxel S-values using EGS4 code) and further photon, electron and the transport of these particles [79]. The code’s newest release, MNCP6,
has improvements in physics (decay emission treatment) and sources (spontaneous
decay). This is important for internal radiation dosimetry, as electrons are a large
contributor to dose. The next code is the electron-gamma-shower (EGSnrc), another Monte Carlo toolkit for ionising radiation transport, spanning from low keV
energies to GeV energies. Originally EGS, EGSnrc improves on charged particle
transport as well as low energy cross sections and geometries.
Geant4 (geometry and tracking), is a general purpose Monte Carlo toolkit which
simulates different particle types for a large range of energies [79]. Geant4 was
created originally for high energy physics scenarios, however developments have
allowed for various applications, including internal dosimetry. Geant4’s physics processes to simulate the radiation dosimetry scenarios. However, Geant4 has various
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physics packages (shown in Figure 2.7) available to simulate different particle energy
ranges. However, the correct physics package for the correct energy range must be
selected in order to obtain accurate results. Thus, for the application in nuclear
medicine the Low Energy Electromagnetic Physics (Livermore) package is selected.
This physics process, developed in 2006 makes use of atomic shell cross section data,
as the structure of the shell is more important at lower energies compared to higher
energies. The Livermore model includes the photo-electric effect, Compton scattering, Rayleigh scattering, gamma conversion, bremsstrahlung and ionisation [72].
These energy ranges can be defined down to energies smaller than 1 keV, making it
valuable for low energy applications.
Phantoms and their development and their place in internal dosimetry (discussed
in Section 1.3). However, as the phantoms generated become more complex, then
the ability to compute them and physics processes occurring within the phantom,
needs to expand. Monte Carlo codes are excellent in simulating high energy physics,
however are poor for handling of nuclear medicine or phantom geometries [75].

Figure 2.7: Available Physics Processes and Models in Geant4 [72]

2.4.4

GATE

GATE, the Geant4 Application for Tomographic Emission, utilises the Geant4 libraries to ”achieve a modular, versatile, scripted simulation toolkit adapted to the
field of nuclear medicine” [75]. The novelty of GATE is that the application allows
Geant4 (which is a pre-requisite for GATE) to manage the kernel and the physics of
the simulation, but allows GATE to create the environment in a user-friendly way.
GATE is the only open source Monte Carlo program with user-friendly simulations
for dosimetry, imaging and radiotherapy [50]. The development of GATE has come
in conjunction with demand for increased demand for accurate, fast and high quality imaging in nuclear medicine, whilst the availability of computer clusters have
increased.
GATE was designed with user friendliness in mind, with no knowledge of C++
required to design programs. Secondly, as most nuclear medicine modalities share
similar geometries and physics principles, software components can be shared from
one context to another. Finally, GATE is modular and is able to develop and evolve
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for new applications [75].
Figure 2.8 shows the layered structure of GATE software. At the centre of GATE
is Geant4 and its physics processes to simulate experiments. The core and application layer make up the developer layer of GATE. The core layer is made up of the
various available classes which form the basis of the GATE program. The classes
define to developers what tools are accessible for use, and how they can utilise these
tools for their development. These include the mandatory Geant4 tools to generate
geometries, the physics classes required to run simulations, generation of interaction events and potential visualisation scenes [50]. Finally, the core layer includes
classes exclusive to GATE, mainly the GATE virtual clock which similarly to its use
in Geant4, is responsible for time management during simulations, and recording
when hits occur. The second component of the development layer is the application
layer. This component builds on the core layer, and is responsible for the modelling of specific objects and processes. For example, the core layer defines the base
class of the volumes, then the application layer contains the classes which allow for
modelling of certain volumes (eg boxes, cylinders) [75]. The classes present in this
layer of the application are also extensions of the movement base class, and can
create specified movements of translation, rotation and oscillations. This layer is
open to expansion, with the potential for the development of new specific volumes
and their movement. The final layer is the user layer, which utilises scripts to allow
for users with no coding experience to run simulations. This is possible through
the inner layers of GATE, with the development layer classes establishing all the
C++ coding required [80]. So when the user wishes to create a geometry or source,
all that is required is to generate it using a tree like scenario. First, the user calls
GATE, and then the subset class for example the geometry or source. Each subset
class will contain commands which are installed in the development layer, whether
it be setting the length of the world or attaching an actor to a phantom to measure
dose. The scripts, also known as macros, are ASCII text files (.mac files). Lines
containing # are comments, however male and female components are commented
out depending on which gender is selected. The macros are executed in a LINUX
machine or through a GATE virtual machine, calling GATE followed by the name
of the macros file.
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Chapter 3
Method and Materials
3.1

Adult Voxel Reference Computational Phantoms

The ICRP since their 2007 publication, ICRP 103 [35], have been promoting the
use of a voxel computational phantom for dosimetric reference data. This need
for an updated reference computational male and female for voxel phantoms came
as a result of the ICRP 89 publication, which updated the ’Basic Anatomical and
Physiological Data for Use in Radiological Protection Reference Values’ [36]. Publication 89 aimed to unify new information on reference anatomy and physiology
which were last updated in 1975 [81]. At the time, the best methodology was the
use of three-dimensional volume pixels (voxels) to define organs and tissues. The
voxel phantoms were generated based on CT images of a male and female patients
with physical characteristics similar to the reference male and female listed in ICRP
89 [36]. The CT images were adapted to fit the reference values given in the previous
publication, which were then released as voxel phantoms in ICRP’s 2009 publication
(ICRP 110, 2009) [33]. Table 3.1 defines the computational and physical properties
of both male and female phantoms. The ICRP 110 phantoms contain an additional
slice of skin on the top and bottom of the phantom to ensure the phantom is wrapped
in skin [33] (this is denoted in Table 3.1 by the additional two slices∗ ). These skin
voxels are included in this study, totalling 140 different organ tissues. The make up
of these organ tissues are detailed in the ICRP 110 publication, including the mass,
density and chemical makeup [33].
Scripts were developed in R statistical voxelised tool [82] to convert the ICRP 110
files into a MHD format image file and a material file to be inputted in GATE, Figure
3.1. To do this, the number of rows, columns and slices were defined from the annals.
The matrix elements were filled with the organ tissue ID from the AF/AM.dat file
(see Section 3.3), detailing where organ tissues sit in the matrix (on a voxel basis).
Each organ is then generated from the organs.dat file, with the make up of each
organ described in the media.dat file.
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Properties
Height (cm)
Mass (kg)
Number of tissue voxels
Slice thickness (voxel height, mm)
Voxel in-plane resolution (mm)
Voxel volume (mm3 )
Number of columns (X)
Number of rows (Y)
Number of slices (Z)

Male (AM)
176
73.0
1 946 375
8.0
2.137
36.54
254
127
220 (+2)∗

26
Female (AF)
163
60.0
3 886 020
4.84
1.775
15.25
299
137
346 (+2)∗

Table 3.1: Main Characteristics of male and female reference computational
phantoms [33]

Figure 3.1: MHD image file of the AM ICRP 110 phantom with fiducial
marker in liver as visualised using AMIDE [83]

3.2

Adult Mesh-type Reference Computational
Phantoms

The development of the mesh reference phantoms is discussed in Section 1.3, with
the ICRP 145 phantom visualisation observed in Figure 3.2 and Figure 3.3. To implement the phantom into GATE, first, the material databases had to be generated

CHAPTER 3. METHOD AND MATERIALS

27

for male and female phantoms. The chemical makeup of organs differ between male
and female phantoms, and require separate databases. The additional file required
to be generated is the RegionAttibuteTable, which labels each regionID as well as
their colour (ratio of red, green and blue or rgb) for visualisation. The phantom
requires no pre-processing and was constructed in GATE by calling the input files
through macros.
In order to implement the ICRP 145 Mesh-type reference computational phantoms, various file formats were required. ICRP 145 utilises polygon mesh (PM)
and tetrahedral mesh (TM) modelling developed from the previous voxelised reference phantom [43]. All files used were of the ASCII form, and the two used for the
mesh phantom are the .node and .ele file extensions. The .node files contain the list
of 3D points which are used to construct the polygons and tetrahedral shapes for
the phantom construction. Each point described in the node has an x, y and z coordinate and is prescribed a boundary marker (either a vertex, edge or face). The next
format is an .ele file which contains a list of tetrahedra to construct the phantom [40].
The tetrahedra call upon the material definitions (.mtl) file, a data directory required to construct the phantom. The .mtl file defines the colour of a material using
three definitions. The Ka defines the ambient colour of the material, the Kb defines
the diffuse colour and Ks defines the specular colour. These three definitions are
made up of a ratio of red, green and blue (rgb), and define the colour of a material.
For this project, ambient colour was chosen to represent the phantom illuminated
by ambient light rather than direct light [40].

Figure 3.2: Adult Female Mesh-type Reference Computational Phantom [43]
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Figure 3.3: Adult Male Mesh-type Reference Computational Phantom [43]

3.3

Implementation of voxel phantom in GATE

ICRP 110 has attached supplemental material including;
• List of media and their elemental compositions (AF/AM media.dat)
• List of skeleton sub-segmentation with composition of red bone marrow (RBM),
yellow bone marrow (YBM) and bone (AF/AM spongiosa.dat)
• List of Organs and tissues of the computational phantom, and associated organ
ID/tissue number (AF/AM organs.dat)
• List of Blood ratios within each media (AF/AM blood.dat)
• File defining where each medium sits (matrix) (AF/AM.dat)
These files have been used to generate a materials database which GATE calls
upon when generating the geometry. The database ICRP110 materials.db was
generated using an Rscript and is generated from the above files . This material
database was called in the world macros, and defines the chemical composition of
any material used in the world as well as size (9m3 ) (including phantom). Next, a
phantom macro file was called, generating the phantom in the world. In order to
utilise this method, a metaimage format was used (header.mhd and rawimage.raw).
These files are generated using an Rscript, which takes the phantom data from the
supplementary ICRP 110 files and generates the geometry files. The Geant4 nested
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parametised method was used to create the navigation volume in Geant4. This
method was utilised due to its efficiency in storing data [80]. The negative of using
this method is the increased time required to run particles, as particles are required
to stop at boundaries of parallelepipeds [75], causing the generation of a supplementary step [80]. Finally, the phantom had to be orientated within the world. The
centre of the phantom was set to the centre of the world and was orientated along
the Z axis (patient supine with superior components in positive Z direction). The
Geant4 physics process utilised was the Emlivermore package, due to its accuracy
at low energies (as discussed in the previous Section 2.4). For gamma’s and electrons, the range cuts were set to 0.1mm within the phantom. A detectors.mac file
contains all the relevant actors which collect data from the simulation runs. The
DoseByRegions actor was used to collect the relevant data from the simulations.
The DoseByRegions actor requires a second input in order to identify and define
regions to collect information. By inputting the ICRP110 GATEgeometry.mhd file,
the actor can identify each region and store the information. The actor outputs
results as a text file and includes:
• ID number
• Volume (mm3 )
• Energy Deposited (MeV) in each region
• Standard Deviation of the Energy Deposited (MeV)
• Square root of the Energy Deposited
• Dose (Gy)
• Standard Deviation of the Dose (Gy)
• Square root of the Dose
• Number of hits in the region (each time primary or secondary particle makes
a step, whether energy deposition occurs or not)
• Number of event hits in the region
The source was implemented in separate source macros for different radionuclides.
Each source macros contained a histogram and describes the energy and frequency
of emissions, as well as the intensity of different emission types. The source was
defined as ’Volume’ to generate a homogeneous and isotropic emission. The entire
decay scheme was simulated. Auger electron’s were not included in this simulation.
There was no minimum threshold applied for X-ray/photon emission. The energy
histograms were taken from the ICRP 107 annals, which contains the nuclear decay
data for dosimetric calculations [31]. In this publication the energies and yields
of radioisotopes are published and organised into separate files for different decay
methods. The ICRP-07.BET file was used for information on beta emitters and
the ICRP-07.RAD file was used for all other decay methods, mainly emission of
photons. This includes the entire decay chain for beta and gamma emission. The
source was classified as a GEANT4 general particle source (GPS), with its energy,
shape, dimension and position begin defined in the macro. Finally, the entire world
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was visualised (using either DAWN or OpenGL visualisation tools). DAWN was
included in the GATE installation, however to use OpenGL it must be included in
the Geant4 installation.

3.4

Implementation of mesh phantom in GATE

The ICRP 145 publication are supported with the following supplementary materials
for both male and female mesh phantoms [43]. The data files for the tetrahedral mesh
(TM) MRCPs are defined in data files of NODE and ELE format files. The NODEformatted files have the list of nodes which the TM phantoms are composed of.
This is accompanied by the ELE-formatted files which have the list of tetrahedrons.
These files work in unison, as each tetrahedron is described by four node IDs listed
in the NODE-format file [43]. The following files accompany the NODE and ELE
files of the ICRP 145 publication which describe the material of the phantom:
• Lists of the media, elemental compositions and densities (media.dat)
• The mass ratios of bone constituents in the bone sites (bone.dat)
• The mass ratios of blood in various body tissues (blood.dat)
• PDF for visualisation
A similar methodology is followed to generate the mesh phantom in GATE: the
material database was used as per the ICRP 110 phantom was to create the world
and define the materials which are used to implement the phantom. To create
the phantom in the world, the .ele file and RegionAttributeTable (includes region
number, name of material, and rgb discussed in Section 3.2) are used. The phantom
is again set to the centre of the world and is orientated along the Z axis (patient
supine with superior components in positive Z direction). For data collection in
tetrahedral mesh geometries, the TetMeshDose actor was used. This actor records:
• Tetrahedron-ID
• Volume (cm3 )
• Density of Tetrahedron material (g cm−3
• Region Marker
• Relative Uncertainty
• Dose (Gy)
Similarly to ICRP110.mac, the ICRP145.mac can be broken down into all its
separate components.
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GATE run parameters

Initial simulations of low particle counts were run on an Intel i7-6700 CPU operating
at 3.40GHz to ensure geometries (phantom and source) were correct. GATE version
9.1 with Geant4 version 10.6.3 were utilised. 10 million particles were simulated
using the Geant4 Emlivermore physics package for each scenario. These are for the
three radionuclides used; Holmium-166, Lutetium-177 and Yttrium-90, for the four
phantoms; ICRP 110 (male and female) and ICRP 145 (male and female), and the
four spherical lesion diameters; 0.1cm, 0.5cm, 1cm and 3cm.

3.6

Determination of S-values for ICRP 110 and
ICRP 145 phantoms

The voxel and mesh phantoms were generated in GATE as described above. The
phantoms were placed in the centre of the world volume, with the phantoms laying
supine along the Z axis (superior anatomy in positive Z direction). The ICRP 145
Adult Female (AF) phantom is shown in Figure 3.4, with the positioning within the
world used for all phantoms. The red sphere within the patient is a 3cm diameter
Ho-166 sphere, located within the liver. The positioning of the lesion was determined
using the ICRP 110 geometry image, generated for the construction of the ICRP
110 phantom within GATE. Preliminary runs were conducted with 3 million particles to confirm the placement of the source in the phantoms. As the range of beta
emission for Holmium-166 is a maximum of 8.7mm, the largest amount of energy
deposited was within the source organ, confirming the placement of the lesion. The
simulations were repeated with 10 million particles per simulation for each scenario.
S-values for the liver, pancreas, gall bladder, small intestine, left and right lung
and the stomach were estimated. The simulations aimed to achieve a coefficient
of variation within the source organ of less than 0.5. The coefficient of variation
was determined to characterise the uncertainties in the Monte Carlo simulations
run. A uniform distribution of three radionuclides: Yttrium-90, Holmium-166 and
Lutetium-177 were all implemented into the male and female phantoms (voxel and
mesh phantoms). Spherical sources were placed in the liver, and were simulated
for four different sphere diameters; 0.1cm, 0.5cm, 1cm and 3cm. The radionuclides
generated from the ICRP 107 include beta and gamma emission, hence the S-values
determined include both emission methods. The centre of the lesion remained constant throughout the simulations sitting in a central position of the liver. The mass
of each region was determined by multiplying the volume of a region by the density
of the region. The energy deposited in each region which is recorded by the DoseByRegion actor, is divided by the mass calculated (J/kg), which is equivalent to
the units for dose (Gy). This was used to determine the S-values, by dividing the
dose by the number of particles (Gy Bq−1 s−1 ). The common units for S-values are
mGy MBq−1 s−1 , so unit conversion was conducted. For the ICRP 145 phantom, the
TetMeshDose actor was utilised. The output of the file includes the tetrahedron
ID, dose in each tetrahedron, uncertainties and the volume of each tetrahedron. In
each tetrahedron, dose per tetrahedron was converted to energy per tetrahedron.
The mass of each tetrahedron was then calculated by multiplying its volume by
the density listed in the ICRP 145 annals. The dose per region was calculated by
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summing each tetrahedron within a region and dividing by the mass sum of all tetrahedron within the volume. A similar calculation was conducted for the uncertainty
per region. The S-values were again determined by dividing the dose in a region by
the number of particles, and conducting unit conversions.

Figure 3.4: AF ICRP 145 mesh phantom world volume placement, red 3cm
diameter 166 Ho source, visualised in DAWN. The dots in the phantom show the
different materials as described in the RegionAttributeTable
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S-values estimated for the ICRP 110 and ICRP 145 phantoms, for the use of
Yttrium-90, Holmium-166 and Lutetium-177 in spherical sources placed in the liver
are shown in the following chapter. Each plot presents the three radionuclides with
four different spherical lesions (0.1, 0.5, 1 and 3cm diameter) for the ICRP 110 female, ICRP 110 male, ICRP 145 female and ICRP 145 male phantoms. The centre
of the lesion remained constant throughout the simulations sitting in a central position of the liver. Using the confine function, the source remained within the liver
volume. Each organ has its mass calculated from the simulation data. The volume
of each voxel/tetrahedron is multiplied by the density of the region of interest to determine its mass. This increases the accuracy of the simulation, as by not using the
weight of each region given in the ICRP annals the weight matches that used in the
simulation exactly. The results presented for organs outside the liver have large statistical uncertainties due to the small number of particles interacting in the volume.
This is due to the relative low abundance of γ-emission, when present, and to the
short range of β-emission. Uncertainties on the S-values are presented in Appendix
A as well as all the S-values for all simulations run. Table A.1 has all S-values for
the ICRP 110 female phantom, Table A.2 the ICRP 110 male, Table A.3 the ICRP
145 female and Table A.4 the ICRP 145 male phantom. This comprehensive set of
data includes the S-values as well as coefficient of variation for each lesion diameter
and radionuclide, with the previous plots a visual representation of this data. This
data also includes the small intestine and stomach which have not been visualised.

Chapter 4
Results
Section 4.1 show the S-values for Liver ← Lesion for the four phantoms. Each
plot contains the three radionuclides and the four different lesion diameters. This
estimation includes the contribution to the healthy liver volume as well as the selfcontribution within the lesion volume. Section 4.2 - 4.5 show the S-values for the
pancreas, gallbladder, left lung and right lung. No error bars have been included in
the liver plots as error bars would not be visible. Error bars have not been included
in the other organ plots and rather have been attached in Appendix A as Coefficient
of Variations.

4.1

S-values for Liver ← Lesion

Figures 4.1 - 4.4 show the S-values calculated in the whole liver with a lesion within
the liver. This value includes the dose recorded within the lesion, so the S-value represents the entire organ. Figures 4.1 - 4.4 show that the S-value determined within
the liver was greatest for the Lutetium-177 isotope and was highest for the female
reference phantoms. The S-values for Yttrium-90 are the lowest for the three radioisotopes. Its greater energy emission during beta decay allows electrons to travel
further before reaching the end of their range. The S-values determined are larger
in females due to the difference in organ mass. In the ICRP 145 annals, males are
listed of having a liver mass of 2.36kg whilst females have a liver mass of 1.81kg. As
the mass is larger in males, the dose value recorded (J/kg) will be smaller, leading
to a smaller S-value. The S-values determined for the ICRP 110 phantoms are also
larger, due to the ICRP 145 phantoms more accurately accounting for blood in the
organ. The ICRP 110 annals have the male liver listed as 1.8kg and the female as
1.4kg, and thus will increase the dose and larger S-values will result.
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Figure 4.1: (Liver ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 110 Female phantom

Figure 4.2: (Liver ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 110 Male phantom
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Figure 4.3: (Liver ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 145 Female phantom

Figure 4.4: (Liver ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166 and
Lu-177 in the ICRP 145 Male phantom
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S-values for Pancreas ← Lesion

The pancreas sits in a medially inferior position to the main lobe of the liver, with
part of the small intestine sitting between the pancreas and the liver. Figures 4.5 4.8 show the S-values calculated for the pancreas due to activity in spherical lesions
in the liver. As the lesion size increases the S-values determined in target organs in
close proximity to the liver will increase. This is observed in Figures 4.6, 4.7 and
4.8, where the S-values calculated for Yttrium-90 increases significantly as for the
3cm diameter lesion. Y-90 is expected to have the largest S-values located outside
the source organ due to its larger maximum and average range for beta particles.
This trend is not followed in Figure 4.5, this is due to large uncertainty due to low
number of hits in the target. It is also expected the S-values increase as the lesion
size increases, however this is not demonstrated for the 0.5cm and 1cm diameter
lesions.

Figure 4.5: (Pancreas ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Female phantom
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Figure 4.6: (Pancreas ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Male phantom

Figure 4.7: (Pancreas ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Female phantom
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Figure 4.8: (Pancreas ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom
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S-values for Gallbladder ← Lesion

The gallbladder sits directly below the liver, flush to the surface of the liver. Figures
4.9 - 4.12 depict the S-values determined for the 3 radionuclides in the gallbladder
due to the lesion within the liver. The results include the dose to the gallbladder
wall, as well as its contents, as provided in the ICRP 110 and 145 annals. Due to the
proximity to the liver, the gallbladder has the second largest S-value across the target
organs discussed, reaching a maximum S-value of 2.588 × 10−8 (mGy M Bq −1 s−1 )
in the ICRP 110 Male phantom for Y-90. The figures also show a larger degree
of variation in S-values for Ho-166 and Lu-177 compared to other target organs
discussed. As the range of these radioisotopes is shorter in tissue, they will deposit
a smaller amount of energy as the target is further from the lesion. Figure 4.10 shows
the trend which best follows the expected behaviour of the simulations. The linear
trend will continue as the lesion size grows, with the largest lesion size depositing
the largest energy onto the target organ. An anomaly of these figures (4.9, 4.11 and
4.12) is the reduction of S-value for 1cm source size, easily identifiable for the Y-90
source. Low particle counts create a larger statistical uncertainty, which is further
amplified in target organs outside the source organ.

Figure 4.9: (Gallbladder ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Female phantom
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Figure 4.10: (Gallbladder ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Male phantom

Figure 4.11: (Gallbladder ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Female phantom
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Figure 4.12: (Gallbladder ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Male phantom
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S-values for Left lung ← Lesion

The left lung sits in a superior and opposing side of the body with respect to the
right lobe of the liver. Due to this increased distance from the liver lesion, the
S-values calculated are smaller relative to the pancreas and gallbladder. S-values
calculated had a maximum value of 4.741 × 10−11 (mGy M Bq −1 s−1 ), however all
values possessed a large uncertainty (minimum coefficient of variation of 44.92).
Due to these uncertainties, it is difficult to determine any trends which occur for the
three radionuclides. There are small variations occurring for the Holmium-166 and
Lutetium-177 sources, but are small relative to the changes in Yttrium-90. Some
anomalies are present in the phantoms presented (Figure 4.13, 4.15, 4.16) which
have the largest S-value for three smaller source diameters (0.1cm, 0.5cm, 1cm).
There are also some simulations where zero hits were recorded in the left lung.

Figure 4.13: (Left lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Female phantom
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Figure 4.14: (Left lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Male phantom

Figure 4.15: (Left lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Female phantom
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Figure 4.16: (Left lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Male phantom
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S-values for Right lung ← Lesion

The right lung sits superior to the right lobe of the liver and has a larger amount
of energy incident on it than the left lung due to its proximity to the liver. The
S-values recorded are larger on average, and has a maximum S-value of 1.295 × 10−9
(mGy M Bq −1 s−1 ) in the ICRP 110 Female phantom for Y-90. Figure 4.20 better
displays the changes in S-values for Ho-166 and Lu-177, with smaller variations in
S-values (less than 1 × 10−11 ) observable. From this figure it is understood that
overall changes in the S-value for target organs have a small change for Ho-166 and
Lu-177 radionuclides. This is due to their short range in soft tissue, and identifies
that lesion size has a smaller impact on S-value variation.

Figure 4.17: (Right lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Female phantom
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Figure 4.18: (Right lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Male phantom

Figure 4.19: (Right lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Male phantom
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Figure 4.20: (Right lung ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Male phantom
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S-values for Left Kidney ← Lesion

The left kidney sits inferior and on the opposing side to the main liver lobe, so a
smaller dose deposition in the organ is expected due to the short range of the beta
emitters tested. This increased distance to the target organ and the small number of
particles simulated also present the issue of poor hit counts, with some simulations
having zero hits. Y-90 has the largest beta energy emitted and therefore has the
largest beta emission range through soft tissue. However, when observing Figures
4.23 and 4.24 the Lutetium-177 radionuclide is depositing the largest amount of dose
in the target region. This is most likely due to the poor statistics of the runs and
will most likely be rectified in further runs. Figure 4.21 follows the expected trend,
where Yttrium-90 deposits the largest amount of dose in the target organ, with the
energy deposited increasing as the lesion size increases.

Figure 4.21: (Left Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Female phantom
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Figure 4.22: (Left Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Male phantom

Figure 4.23: (Left Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Male phantom
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Figure 4.24: (Left Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Male phantom
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S-values for Right Kidney ← Lesion

The right kidney sits directly inferior to the main liver lobe, and will have a larger
amount of energy deposited in the right kidney compared to the left kidney. It is
expected the S-values will increase as the lesion size increases, however this is not
apparent in any of the figures. For all Yttrium-90 plots, either the 0.1cm lesion
or 0.5cm lesion had the largest S-value in all four phantoms, with the statistical
uncertainty being greater in larger lesion sizes. Lutetium-177 S-values were generally
greater than Holmium-166 S-values, as the average range of Lutetium-177 is larger,
this is as expected.

Figure 4.25: (Right Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Female phantom
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Figure 4.26: (Right Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 110 Male phantom

Figure 4.27: (Right Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Male phantom
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Figure 4.28: (Right Kidney ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90,
Ho-166 and Lu-177 in the ICRP 145 Male phantom
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S-values for Spleen ← Lesion

The spleen is an organ that sits laterally to the stomach, sitting behind the left ribs.
It is a component of the lymphatic system, and works to filter blood. It is a small
organ, so the number of hits in this region is expected to be small, as well due to
its anatomic location counts are expected to be smaller. In Figure 4.29, 4.30 and
4.31, Lutetium-177 has larger S-values in the Spleen than Yttrium-90, which does
not agree with the theory presented. This is due to the small number of hits in the
region, with large statistical uncertainties present for all data.

Figure 4.29: (Spleen ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Female phantom
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Figure 4.30: (Spleen ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 110 Male phantom

Figure 4.31: (Spleen ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom
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Figure 4.32: (Spleen ← Lesion) S-values (mGy M Bq −1 s−1 ) for Y-90, Ho-166
and Lu-177 in the ICRP 145 Male phantom
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S-values for all organs in ICRP 145 male
phantom for Ho-166, Lu-177 and Y-90 for 1cm
diameter spherical source

Figures 4.33-4.35 show all non-zero S-values in the ICRP 145 male phantom for Ho166, Lu-177 and Y-90 for 1cm diameter spherical source. The logarithmic scale was
used to demonstrate the doses to organs outside the liver in a graphical manner.
Due to the low hits in organs outside the liver, logarithmic values allow for this
visualisation. For all radionuclides, the liver is estimated to have the largest S-value,
due to the lesion sitting within the liver volume and the short range of beta emission.
The S-value in the liver is largest for 166 Ho, at 5.793 × 10−7 mGy M Bq −1 s−1 for
1cm diameter spherical source. 90 Y , has the smallest estimated S-value in the liver
with 5.571 × 10−8 mGy M Bq −1 s−1 , a factor of 10 smaller than both Holmium-166
and Lutetium-177. It is observed the amount of organs in which hits were recorded
in for the radionuclides, with Lu-177 recording hits in 56 organ IDs. Y-90 recorded
hits in 37 organ IDs whilst Ho-166 hits were recorded in only 29. Amongst all
three radionuclides, the gall bladder and right adrenal received relatively large dose
amongst organs outside the liver. Only one phantom was selected as the results
in organs outside the liver have large uncertainties , and will be explored for all
phantoms in future works.

Figure 4.33: S-value (Organs ← Lesion) ICRP 145 Male Ho-166 1cm
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Figure 4.34: S-value (Organs ← Lesion) ICRP 145 Male Lu-177 1cm

CHAPTER 4. RESULTS
60

Figure 4.35: S-value (Organs ← Lesion) ICRP 145 Male Y-90 1cm
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Phantom Comparison

Figures 4.36 shows the variation in S-values between each phantom: ICRP 110
male, ICRP 110 female, ICRP 145 male and ICRP 145 female, for the four spherical
source sizes with Holmium-166. It is observed that the ICRP 110 Female phantom
has the highest S-value recorded of 9.838 × 10−7 mGyM Bq −1 s−1 for the 3cm diameter spherical source, and the ICRP 145 Male phantom has the lowest S-value of
5.784 × 10−7 mGyM Bq −1 s−1 for the 3cm diameter spherical source. However, when
considering the mass of liver for each phantom, observed in Table 4.1, the result is
seen in Figure 4.37. The ICRP 110 Female phantom still has the largest S-value for
no mass dependence, however the remaining three phantoms are clustered within
0.004 × 10−6 mJM Bq −1 s−1 .

Organ
Liver Mass (g)
Liver Volume (cm3 )

ICRP
Female
1400
1333.3

110
Male
1800
1714.3

ICRP
Female
1810
1707.5

145
Male
2360
2226.4

Table 4.1: Liver mass and volume for ICRP 110 and 145 phantoms [33], [43]

Figure 4.36: S-value (Liver ← Lesion) for ICRP 110 and 145 phantoms, using
four different sized Holmium-166 spherical sources
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Figure 4.37: S-value (Liver ← Lesion) for ICRP 110 and 145 phantoms, using
four different sized Holmium-166 spherical sources with no mass dependence
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Chapter 5
Discussion
This project investigated S-values for 3 radionuclides used in targeted radionuclide
therapy (Lu-177, Ho-166, Y-90) when the radiopharmaceutical is locally administered in liver lesions. The study compared S-values from spherical lesions in the
liver to neighbouring organs. The S-values were calculated using the Geant4/GATE
Monte Carlo tool and were conducted on the ICRP 110 voxel reference phantoms
and the ICRP 145 mesh reference phantoms with 10 million particles run for each
simulation.
For ICRP 110 and ICRP 145 males and females phantoms, Lutetium-177 deposited
the highest S-value in liver compered to Ho-166 and Y-90. It has to be noted that
the S-values for the liver include the healthy tissue as well as the lesion. For liver,
the S-values ranged from 1.292 × 106 mGy M Bq 1 s1 (Lu-177, sphere diameter = 0.5
cm) to 5.577 × 108 mGy M Bq 1 s1 (Y-90, sphere diameter = 0.1 cm). It was found
that the diameter of the lesion (from 0.1 cm to 3 cm sphere) had no significant
impact on the S-values recorded within the liver, as most of the energy emitted by
the radionuclides is deposited within the lesion or within the healthy liver tissue.
As the Yttrium-90 lesion has the largest beta emission energy, the beta particles
have a longer maximum and average path length, and therefore will escape the liver
tissue more readily. This results in a smaller S-value produced within the liver,
however produces a greater S-value in organs surrounding the liver (as shown in
graphs 4.5 to 4.32. Yttrium-90’s S-values range from 9.455 × 108 mGy M Bq 1 s1 to
5.571×108 mGy M Bq 1 s1 , which is about 7% of the highest S-value for Lutetium-177
in the ICRP 110 Female Phantom. Holmium-166‘s S-value range from 9.840 × 107
mGy M Bq 1 s1 to 5.788 × 108 mGy M Bq 1 s1 ,showing a behaviour which is between
Y-90 and Lu-177. As expected, Lutetium-177 will deliver the largest amount of
locally deposited dose whilst depositing the lowest amount of radiation in neighbouring organs. In fact, the mean penetration range of 670 µm will result in a large
amount of energy being deposited within the lesion itself. Given the short range of
the beta emissions and the low abundance of the gamma emissions, when present,
the liver S-values showed the lowest uncertainty. The S-values recorded outside the
liver recorded a coefficient of variation greater than 5%. In some cases, the CV
was as high as 100% due to the nature of the radionuclides. In Yttrium-90 (purely
beta emitter), the maximum range of the beta particle is 11mm, so organs outside
this (or close to) this range will expect low to no hits. When simulating 10 million
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particles, one hit will cause a coefficient of variation of 100%.

Moreover, the S-values estimated for target organs outside the liver are expected
to increase with the lesion size due to their proximity to the lesion. However, most
plots produced in Chapter 5 had anomalies where smaller lesion sizes would produce larger S-values than larger lesion sizes. This is mainly due to an increased
statistical uncertainty as the lesion is further away from the target organ. To reduce
this uncertainty, and to improve the results the number of particles run will have to
increase. In order to generate results with some statistical certainty, it is aimed that
all S-values produced have all coefficients less than 1. In order to reduce uncertainty
on the produced S-values, a higher number of particles should be run. The macros in
future will be simulated and utilised on the NCI GADI supercomputer. The use of
the cluster will be used to perform simulations, visualisations and calculations. Not
only does GADI allow for faster simulation run times and job splitting, but utilises
Geant4 version 10.7, to ensure up to date results. GADI utilises 155 thousand CPU
cores, 567 Terabytes of memory and 640 GPUs to efficiently run simulations. Jobs
are submitted to the NCI through pbs scripts, defining how the job is set up and
the commands to be executed.
The results also showed that the female reference phantoms produced a greater
S-value than their male counterparts. As the lesion sizes and central position remained constant throughout the simulations, the only variation is due to the mass of
the organs. In the ICRP 145 annals [43], the male liver is 2.36 kg whilst the female
is 1.81 kg. As the S-values are calculated using the dose (J/kg Number of particles
simulated), the S-value will be increased for a smaller mass. From the comparison of
the female and male phantoms, it was determined that the (Liver Lesion) S-values
were 130% of the male phantom for the respective phantom. This ratio matches
that of the weight ratios for the liver masses given in the annals. From the results
it is also determined the S-values for the ICRP 110 voxel phantom are greater than
that of the ICRP 145 mesh phantom. This is partly due to the weight of the organs
from the ICRP 110 annals [33]. The male liver is listed as 1.8 kg whilst the female
is 1.4 kg. This reduction in weight again will increase the S-values recorded. When
converting the voxel phantom to the mesh phantom, some updates were included
which includes the blood within the liver as weight to the organ. This has caused a
change in the mass of the liver, hence a change in S-values determined. These have
been noted in the ICRP133 annals [30]. The results of the (Liver Lesion) S-values
found the mesh phantom was approximately 76% of the respective voxel phantom.
When observing the two ICRP phantoms, there is general limitations in the voxel
model which have been rectified in the mesh phantom development. Due to the
nature of the voxel phantom (limited resolution from the CT images used to generate the phantom), blood vessels and bone marrow is unable to be determined in
the phantom. For this study, this has a limited impact due to the focus on soft
tissue organs, however into the future, the research should utilise the mesh phantom
for its higher accuracy on anatomical features. This accuracy is seen in the results
presented, with a discrepancy of results between the ICRP 110 and the ICRP 145
phantoms. The main cause of disparity is due to the organ mass not including blood
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in the voxel phantom whilst it does in the mesh phantom. This change of weight
will alter the dose value calculated. In future calculations, it is possible to record
the energy deposited on each source and target organ, and calculate the dose using
a standard weight for males and females. However, this may create uncertainties for
the voxel phantom, due to the nature of voxels creating a rigid surface area. This
will result in a larger area (number of voxels) being considered liver tissue compared
to the mesh phantom (number of tetrahedron).
The source sizes selected were chosen to represent various tumour sizes within the
liver, with a maximum sphere diameter of 3cm. In future studies, it is planned to
run simulations that determine the dose to healthy liver tissue by subtracting the
energy deposited within the lesion from the energy deposited in the whole liver and
dividing by the healthy liver mass. It is expected that the smaller lesion sizes will
deposit a larger amount of dose to healthy tissue compared to larger lesion sizes, as
the larger lesions will have some beta particles which escape the liver and deposit
dose in other tissue.
In order to understand the nature of each radioisotope, simulations should investigate the separate contributions of the beta and the gamma emissions. This will
allow for the makeup of each radionuclide’s dose deposition to be observed. To
apply this work in a clinical scenario, the absorbed doses can be determined for
each radionuclide by looking at the effective half-life (of each radionuclide and biological half-life for microspheres) and activity administered. This can be used to
generate dosimetry information for patients and nuclear medicine staff on common
procedures.

Chapter 6
Conclusion
The aim of this study was to investigate dose to neighbouring organs from activities
of Lutetium-177, Holmium-166 and Yttrium-90 in liver lesions. This was conducted
by implementing spherical sources in the liver of the ICRP 110 and ICRP 145
phantoms in Geant4/GATE. It was shown that Lutetium-177 recorded the highest
S-value (Liver ← Lesion), while Yttrium-90 recorded the lowest S-value (Liver ←
Lesion). It was demonstrated the dose to the liver for Holmium-166 was largest
for the ICRP 110 female phantom when there was no mass dependence, whilst the
remaining three phantoms have similar dose deposition on the liver. Due to the
small number of particles simulated (107 ), the statistical uncertainty outside of the
source organ was significant and future work will aim to increase the number of
particles simulated to provide S-values for all target organs within the body with
reasonable statistics. A further investigation may have the liver volume and mass to
be matched for all models to determine dose. This work will improve understanding
of radiation dose to neighbouring organs from trans-arterial radioembolisation using
Lutetium-177, Holmium-166 and Yttrium-90.
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Appendix A
Table of S values and Coefficients
of variation
Table A.1 - A.4 present the S values (mGy M Bq −1 s−1 ) and the associated coefficient
of variation for organs surrounding and including the liver. The four tables show
these S values for the four phantoms; ICRP 110 female, ICRP 110 male, ICRP
145 female and ICRP 145 male in order. 10 million particles were simulated for
each Monte Carlo simulation, with the coefficient of variation less than 1 for S
values within the source organ a desirable result. The coefficient of variations are
expressed as a real number, which when multiplied to the S value obtained, results
in the error for the S value.

77

0.1cm
S [mGy M Bq −1 s−1 ]
9.455E-08
9.833E-07
1.289E-06

2.209E-10
7.788E-12
1.641E-13

1.298E-10
9.605E-11
1.235E-11

1.468E-10
0
5.519E-13

5.435E-13
2.912E-12
2.672E-12

2.617E-10
1.469E-11
5.443E-11

0
1.831E-12
1.428E-13

Liver
Y-90
Ho-166
Lu-177

Pancreas
Y-90
Ho-166
Lu-177

Gall bladder total
Y-90
Ho-166
Lu-177

Small Intestine Total
Y-90
Ho-166
Lu-177

Lung Left
Y-90
Ho-166
Lu-177

Lung Right
Y-90
Ho-166
Lu-177

Stomach Total
Y-90
Ho-166
Lu-177

0
100
100

21.932
73.520
42.733

100
100
100

87.011
0
100

51.002
100
90.727

92.647
100
100

Coefficient of Variation
0.166
0.183
0.142

9.369E-11
2.237E-12
9.343E-14

6.671E-10
7.043E-12
3.102E-11

4.040E-11
4.985E-13
1.348E-13

6.607E-11
1.085E-12
2.019E-12

1.216E-09
0
5.794E-11

1.911E-10
6.184E-13
4.662E-12

0.5cm
S [mGy M Bq −1 s−1 ]
9.446E-08
9.839E-07
1.292E-06

100
100
100

60.625
79.705
53.587

100
100
100

99.285
98.889
92.821

95.178
0
100

88.771
100
100

Coefficient of Variation
0.149
0.182
0.189

3.502E-12
7.643E-12
5.324E-12

2.921E-10
5.022E-11
4.189E-11

5.633E-12
0
1.073E-12

0
0
5.536E-12

6.193E-10
0
4.194E-11

0
4.626E-12
2.951E-12

1cm
S [mGy M Bq −1 s−1 ]
9.437E-08
9.828E-07
1.289E-06

100
100
75.120

15.032
69.877
30.953

63.627
0
79.851

0
0
49.533

76.793
0
38.232

0
100
77.928

Coefficient of Variation
0.163
0.183
0.059

0
0
6.564E-12

1.295E-09
3.170E-11
3.445E-11

0
0
2.806E-12

7.237E-11
8.035E-13
3.330E-12

9.951E-10
2.811E-11
8.955E-11

1.139E-13
3.941E-12
4.691E-12

3cm
S [mGy M Bq −1 s−1 ]
9.423E-08
9.829E-07
1.289E-06

0
0
59.676

50.627
65.503
16.702

0
0
93.814

57.020
100
62.266

82.704
83.391
49.657

100
100
66.498

Coefficient of Variation
0.146
0.182
0.059
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Table A.1: ICRP 110 Female (AF) S values and Coefficient of variations. For
a spherical lesion located in the liver ranging in diameter from 0.1cm to 3cm.

0.1cm
S [mGy M Bq −1 s−1 ]
7.295E-08
7.585E-07
9.948E-07

2.883E-10
1.495E-11
2.725E-11

1.257E-08
9.469E-11
1.905E-10

4.918E-11
3.034E-12
2.837E-12

0
1.546E-12
6.374E-13

5.131E-11
6.569E-12
1.124E-11

9.453E-12
9.181E-13
5.902E-12

Liver
Y-90
Ho-166
Lu-177

Pancreas
Y-90
Ho-166
Lu-177

Gall bladder total
Y-90
Ho-166
Lu-177

Small Intestine Total
Y-90
Ho-166
Lu-177

Lung Left
Y-90
Ho-166
Lu-177

Lung Right
Y-90
Ho-166
Lu-177

Stomach Total
Y-90
Ho-166
Lu-177

99.447
100
97.995

75.762
91.638
28.921

0
100
100

72.586
100
74.517

4.254
76.501
39.637

82.425
97.193
34.008

Coefficient of Variation
0.166
0.183
0.084

0
7.170E-13
1.589E-11

1.091E-11
6.243E-12
1.526E-11

2.765E-11
8.246E-13
6.596E-13

9.855E-11
2.529E-12
8.688E-12

1.361E-08
1.446E-10
3.441E-10

7.146E-11
3.640E-14
2.656E-11

0.5cm
S [mGy M Bq −1 s−1 ]
7.279E-08
7.605E-07
9.947E-07

0
100
60.027

53.399
63.115
61.124

76.863
100
73.240

64.176
100
63.092

7.015
73.168
33.505

36.225
100
39.258

Coefficient of Variation
0.154
0.182
0.085

2.470-11
3.806E-12
8.040E-12

2.651E-10
3.384E-12
2.299E-11

2.869E-12
0
4.843E-12

5.762E-12
7.104E-13
5.047E-12

1.678E-08
1.019E-10
3.214E-10

6.440E-11
1.335E-11
2.242E-11

1cm
S [mGy M Bq −1 s−1 ]
7.296E-08
7.606E-07
9.943E-07

100
100
50.843

75.315
74.163
37.729

100
0
96.612

55.125
100
38.477

15.463
81.647
24.563

17.162
70.004
29.157

Coefficient of Variation
0.163
0.182
0.059

4.840E-12
1.906E-12
7.196E-12

3.000E-10
1.173E-11
2.013E-11

4.741E-11
1.297E-13
1.004E-12

3.514E-11
4.109E-12
4.161E-12

2.588E-08
1.111E-10
2.394E-10

1.754E-10
9.757E-12
2.229E-11

3cm
S [mGy M Bq −1 s−1 ]
7.284E-08
7.589E-07
9.950E-07

76.635
100
60.966

86.903
87.063
44.957

100
100
79.303

97.011
86.886
57.461

2.975
81.387
23.064

51.270
100
29.675

Coefficient of Variation
0.169
0.182
0.059
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Table A.2: ICRP 110 Male (AM) S values and Coefficient of variations. For a
spherical lesion located in the liver ranging in diameter from 0.1cm to 3cm.

0.1cm
S [mGy M Bq −1 s−1 ]
7.262E-08
7.558E-07
9.883E-07

0
9.615E-13
9.876E-13

3.475E-11
1.540E-11
6.082E-12

1.224E-10
3.925E-14
9.266E-13

0
2.466E-12
7.651E-13

4.536E-10
1.393E-11
3.924E-11

6.277E-11
8.168E-13
4.688E-12

Liver
Y90
Ho166
Lu177

Pancreas
Y90
Ho166
Lu177

Gall bladder total
Y90
Ho166
Lu177

Small Intestine Total
Y90
Ho166
Lu177

Lung Left
Y90
Ho166
Lu177

Lung Right
Y90
Ho166
Lu177

Stomach Total
Y90
Ho166
Lu177

90.505
100
64.466

5.906
44.612
16.430

0
71.028
44.923

57.751
100
72.866

100
100
64.777

0
81.388
60.528

Coefficient of Variation
0.147
0.181
0.084

0
4.174E-14
1.394E-12

4.725E-10
1.884E-11
3.342E-11

0
0
4.276E-12

1.218E-12
0
2.104E-12

2.637E-10
0
2.045E-11

0
0
7.871E-12

0.5cm
S [mGy M Bq −1 s−1 ]
7.244E-08
7.557E-07
9.884E-07

0
100
100

9.182
43.810
34.094

0
0
84.802

100
0
100

79.155
0
80.792

0
0
100

Coefficient of Variation
0.146
0.188
0.167

1.963E-12
3.284E-12
3.072E-10

5.802E-10
1.920E-11
3.864E-11

2.483E-11
1.511E-12
1.641E-12

2.134E-11
7.728E-14
4.604E-13

8.052E-11
1.703E-11
5.951E-11

0
3.969E-13
3.641E-12

1cm
S [mGy M Bq −1 s−1 ]
7.265E-08
7.546E-07
9.888E-07

100
0.1
98.832

7.301
38.712
10.681

81.570
98.131
65.112

56.987
0.1
89.366

65.368
80.910
88.059

0
0.073
75.861

Coefficient of Variation
0.153
0.152
0.062

0
4.764E-13
7.940E-12

7.250E-10
9.738E-12
3.360E-11

0
1.181E-13
2.162E-12

5.229E-11
2.738E-14
0

2.832E-11
1.739E-13
2.664E-11

6.050E-11
3.162E-12
5.987E-12

3cm
S [mGy M Bq −1 s−1 ]
7.239E-08
7.541E-07
9.887E-07

0
92.548
57.072

5.673
58.277
11.316

0
100
52.409

41.306
100
0

44.071
100
46.580

67.816
100
65.180

Coefficient of Variation
0.1512
0.193
0.063
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Table A.3: ICRP 145 Female (AF) S values and Coefficient of variations. For
a spherical lesion located in the liver ranging in diameter from 0.1cm to 3cm.

0.1cm
S [mGy M Bq −1 s−1 ]
5.581E-08
5.788E-07
7.583E-07

8.934E-11
6.956E-12
1.112E-11

1.000E-09
3.221E-11
1.805E-10

1.735E-11
2.369E-12
6.045E-12

2.977E-11
1.373E-12
0

2.477E-11
3.619E-12
7.393E-12

1.018E-10
6.968E-12
5.166E-12

Liver
Y90
Ho166
Lu177

Pancreas
Y90
Ho166
Lu177

Gall bladder total
Y90
Ho166
Lu177

Small Intestine Total
Y90
Ho166
Lu177

Lung Left
Y90
Ho166
Lu177

Lung Right
Y90
Ho166
Lu177

Stomach Total
Y90
Ho166
Lu177

100
97.317
78.814

53.941
69.000
30.121

51.330
100
0

80.148
100
71.996

26.396
78.460
53.419

77.626
89.326
58.244

Coefficient of Variation
0.151
0.186
0.085

2.975E-13
2.687E-12
9.317E-12

2.708E-11
3.765E-12
8.958E-12

0
4.046E-14
1.025E-12

8.581E-12
2.359E-12
2.127E-12

1.340E-09
8.479E-11
2.103E-10

1.087E-11
8.270E-12
1.474E-11

0.5cm
S [mGy M Bq −1 s−1 ]
5.577E-08
5.794E-07
7.584E-07

83.622
88.115
65.461

45.038
78.259
26.917

0
100
92.334

65.692
97.482
68.997

28.415
88.479
45.980

37.713
57.964
39.926

Coefficient of Variation
0.147
0.188
0.087

2.041E-12
6.496E-12
6.271E-12

1.782E-11
1.025E-12
8.411E-12

6.827E-13
0
1.679E-12

8.023E-11
3.046E-14
1.164E-12

9.475E-10
1.692E-11
1.064E-10

7.980E-12
7.587E-12
1.317E-11

1cm
S [mGy M Bq −1 s−1 ]
5.571E-08
5.791E-07
7.591E-07

73.181
98.383
56.549

45.164
92.875
20.897

100
0
49.871

29.294
100
72.605

16.838
69.471
40.405

44.348
91.828
35.427

Coefficient of Variation
0.148
0.190
0.062

3.246E-13
0
6.573E-11

5.661E-11
5.188E-12
9.130E-12

7.586E-12
0
2.349E-14

0
6.223E-13
4.997E-12

1.380E-09
1.137E-11
6.879E-11

1.892E-10
3.496E-12
1.173E-11

3cm
S [mGy M Bq −1 s−1 ]
5.580E-08
5.793E-07
7.587E-07

100
0
99.475

44.258
69.608
20.257

100
0
100

0
100
91.408

14.037
92.380
28.516

48.111
92.307
33.735

Coefficient of Variation
0.151
0.192
0.062
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Table A.4: ICRP 145 Male (AM) S values and Coefficient of variations. For a
spherical lesion located in the liver ranging in diameter from 0.1cm to 3cm.

Appendix B
Requirements of
Radiopharmaceuticals
All radiopharmaceuticals produced for biological and clinical use must:
• Use ’pure’ radionuclide in the radiosynthesis of the radiopharmaceutical
• Have a high radiochemical purity, in correct chemical form (chemical purity)
and in high specific activity
• Have the radiolabel incorporated in the correct position in the molecule
• Satisfy appropriate ’product release criteria’
• Bind, associate or incorporate within the biological target with high affinity,
selectivity and specificity
• Be metabolically stable and must not interfere with the parent radiopharmaceutical or biological target
• Display appropriate kinetics, clearance rate and route, biological half-life
The product release criteria are quality control measures completed in nuclear
medicine departments to ensure the radiopharmaceuticals produced are up to standard, and can be used in practice. These include:
• Physical appearance (colour, particle size, turbidity)
• Chemical purity
• pH
• Radiochemical purity
• Specific activity
• Radionuclidic purity
• Endotoxin (LAL)
• Sterility
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• Environmental (Lab, air, benches, hot cells)
• Equipment (Cyclotron, radiochemistry molecules, instruments)
The product release criteria contain two important measurements relevant to radiopharmaceuticals and nuclear medicine. These are the compounds radiochemical
purity and specific activity. Radiochemical purity is defined as the total radioactivity
in the desired chemical form in the radiopharmaceutical sample. It is determined
by measuring the half-lives and characteristic radiation emitted by individual radionuclides. This differs to the radionuclidic purity, which is the fraction of total
radioactivity in the form of the desired radionuclide present in the radiopharmaceutical. Possible contamination in the sample can create an increased dose to the
patient, and can cause incorrect counting rates in images.
The specific activity is defined as the amount of radioactivity per mass equivalent.
The radionuclide has a large influence on the total mass of the radiopharmaceutical
as the pharmaceutical mass is generally small. In order to not impact upon the
biological processes occurring, the mass of the radionuclide must be low and hence
the mass of the radiopharmaceutical must also be kept low. In order to keep the
mass low and to fulfil its job in providing enough signal to detectors, the specific
activity must be high [84].
A radionuclide may contain stable isotopes of the element of interest, called a carrier.
If the sample doesn’t contain a stable isotope of the element, it is called carrier free.
The greatest possible specific activity is the carrier-free specific activity (CSFA), as
it contains no stable isotopes in the sample [4]. These values are critical, as standardisation and consistency between and within nuclear medicine departments is
important to ensure patient safety and correct dosages.
Other properties in the product release criteria are still important in the assessment of radiopharmaceuticals. The chemical purity is the fraction of the material
in the desired chemical form of a sample. This is important as unwanted chemical
impurities may cause toxic effects to patients, but also may cause incorrect labelling.
The pharmaceutical which the radionuclide is attached to is also referred to as a
tracer. A tracer is a radio-labelled molecule which follows a physiological or biochemical process. A suitable tracer will have known behaviours and is predictable,
doesn’t impact on the physiological or biochemical processes, has a small mass relative to the natural substance, and has a negligible difference between its mass and
the mass of the radioisotope [4]. Some radiopharmaceuticals also require specific
considerations for different applications. This includes the type and energy of emissions, which determine the availability of useful photons or gamma-rays for counting.
Energies of 50-600 keV are useful for external detection as energies below this are
highly likely to be absorbed in the body and won’t be detected. This also increases
dose to patients without providing useful information to practitioners. Finally, the
physical half life of the radionuclide needs to be within the range of seconds to days
(preferably minutes to hours), to allow for preparation, injection and imaging of the
radiopharmaceutical. It is important that the half life is not extensively long, as a
large part of the dosage will be incurred on the patient after the imaging procedure
has occurred.
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Nuclear medicine can be separated into diagnostic and therapeutic (more recently
theranostic) dependent upon energies and half-life of radiopharmaceuticals. Diagnostic radiopharmaceuticals are primarily used for the imaging of disease in the
body, whilst therapeutic radionuclides are used for the treatment of the disease. Diagnostic radiopharmaceuticals should have a short effective half-life to reduce dose
to the patient whilst achieving the clinical goal. Diagnostic radiopharmaceuticals
should also only emit gamma radiation to reduce dose to the patient to be easily
imaged by gamma cameras. These pharmaceuticals should also have a high affinity
for the target organ to reduce dose to non-target organs. This varies to therapeutic
radiopharmaceuticals which should have particle emission (beta, alpha emission) to
effectively treat tumorous cells. They should also have a relatively long half life
(days) to allow the radiopharmaceutical enough time to treat the tumorous cells.
A high activity is required to kill the cells as well. These considerations are all
considered by a nuclear medicine physician and nuclear medicine physicist for the
imaging and treatment of tumours cells in the body.
This demonstrates how vital radionuclides are in nuclear medicine, and highlights
the rigorous preparation that needs to be completed.

